1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. (2001) Cancer Statistics, 2001. CA Cancer Journal for Clinicians, 51(1):15.

2. Baade PD, Coory MD, Aitken JF. (2004) International trends in prostate-cancer mortality: the decrease is continuing and spreading. Cancer Causes Control, 15(3): 237-41.

3. Bartsch G, Horninger W, Klocker H, Reissigl A, Oberaigner W, Schonitzer D, Severi G, Robertson C, Boyle P; Tyrol Prostate Cancer Screening Group.(2000) Decrease in prostate cancer mortality following introduction of prostate specific antigen screening in the federal state of Tyrol, Austria. Journal of Urology 2000, 163(4):88.

4. Etzioni, R, Legler, JM, Feuer, EJ, Merrill, RM, Cronin, KA, Hankey, BF. Cancer surveillance series: interpreting trends in prostate cancer--part III: Quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality. Journal of the National Cancer Institute 1999, 91(12):1033.

5. Hankey BF, Fuer EJ, Clegg LX, Hayes RB, Legler JM, Prorok PC, Ries LA, Merrill RM, Kaplan RS. Cancer Surveillance Series: Interpreting trends in prostate cancer – Part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality and survival rates. J Natl Cancer Inst, 1999, 91:1017-1024.

6. Schroder FH, Kranse R. Verification bias and the prostate-specific antigen test--is there a case for a lower threshold for biopsy? N Engl J Med,2003; 349(4):393-5.

7. Partin AW, Stutzman RE. Elevated prostate-specific antigen, abnormal prostate evaluation on digital rectal examination, and transrectal ultrasound and prostate biopsy. Urol Clin North Am,1998; 25(4):581-9.

8. Jhaveri FM, Klein EA, Kupelian PA, Levin HS. Declining rates of extracapsular extension after radical prostatectomy: evidence for continued stage migration. J Clinical Oncology, 1999; 17(10):3167-72.

9. Brawer, MK. Prostate-specific antigen: critical issues. Urology, 1994; 44(6A Suppl):9.

10. Carter, HB, Pearson, JD. Prostate-specific antigen testing for early diagnosis of prostate cancer: formulation of guidelines. Urology 1999, 54(5):780.

11. Gann PH, Hennekens CH, Sampfer MJ. A prospective evaluation of plasma prostate specific antigen for detection of prostatic cancer. JAMA, 1995, 273:289-94.

12. Smith DS, Catalona WJ, The nature of prostate cancer detected through prostate specific antigen based screening. J Urol, 1994, 152:1732-6.

13. Hoedemaeker RF, Rietbergen JB, Kranse R, Schröder FH, van derKwast TH. Histopathological prostate cancer characteristics at radical prostatectomy after population based screening. J Urol, 2000, 164:411-5.

14. Luboldt HJ, Bex A, Swoboda A, Husing J, Rubben H. Early detection of prostate cancer in Germany: a study using digital rectal examination and 4.0 ng/ml prostate-specific antigen as cutoff. Eur Urol, 2001, 39:131-7.

15. Freedland SJ, Presti JC Jr, Amling CL, Kane CJ, Aronson WJ, Dorey F, Terris, MK. SEARCH Database Study Group. Time trends in biochemical recurrence after radical prostatectomy: results of the SEARCH database. Urology, 2003, 61:736-741.

16. Labrie F, Candas B, Dupont A, Cusan L, Gomez JL, Suburu RE, Diamond P, Levesque J, Belanger A.. Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial. Prostate 1999, 38(2):83-91.

17. Kirby, RS, Christmas, TJ, Brawer, MK. Prostate cancer. London: Times Mirror International Publishers. 1996.

18. Peehl DM, Feldman D. (2004). "Interaction of nuclear receptor ligands with the Vitamin D signaling pathway in prostate cancer." J Steroid Biochem Mol Biol. 92(4): 307-315.

19. Chung LW, Baseman A, Assikis V, Zhau HE. (2005). "Molecular insights into prostate cancer progression: the missing link of tumor microenvironment." J Urol 173(1): 10-20.

20. Fearon ER. (1997). "Human cancer syndromes: clues to the origin and nature of cancer." Science 278(5340): 1043-1050.

21. Cannon LBD, Skolnick M, Hunt S, Lyon J, Smart C. " Genetic epidemiology of prostate cancer in the Utah Mormon genealogy." Cancer Surv, 1982; 1(47): 47-69.

22. Steinberg GD, Carter B, Beaty T, Childs B, Walsh P. (1990). "Family history and the risk of prostate cancer." Prostate 17: 337-347.

23. Xu JDL, Chang BL, Adams TS, Turner AR, Meyers DA, Eeles RA, Easton DF, Foulkes WD, Simard J, Giles GG, Hopper JL, Mahle L, Moller P, Bishop T, Evans C, Edwards S, Meitz J, Bullock S, Hope Q, Hsieh CL, Halpern J, Balise RN, Oakley-Girvan I, Whittemore AS, Ewing CM, Gielzak M, Isaacs SD, Walsh PC, Wiley KE, Isaacs WB, Thibodeau SN, McDonnell SK, Cunningham JM, Zarfas KE, Hebbring S, Schaid DJ, Friedrichsen DM, Deutsch K, Kolb S, Badzioch M, Jarvik GP, Janer M, Hood L, Ostrander EA, Stanford JL, Lange EM, Beebe-Dimmer JL, Mohai CE, Cooney KA, Ikonen T, Baffoe-Bonnie A, Fredriksson H, Matikainen MP, Tammela TLj, Bailey-Wilson J, Schleutker J, Maier C, Herkommer K, Hoegel JJ, Vogel W, Paiss T, Wiklund F, Emanuelsson M, Stenman E, Jonsson BA, Gronberg H, Camp NJ, Farnham J, Cannon-Albright LA, Seminara D; The ACTANE Consortium. "A combined genomewide linkage scan of 1,233 families for prostate cancer-susceptibility genes conducted by the international consortium for prostate cancer genetics." Am J Hum Gene, 2005; 77(2): 219-229.

24. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, Pukkala E, Skytthe A, Hemminki K. "Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland." N Engl J Med, 2000; 343(2): 78-85.

25. Baker SG, Lichtenstein P, Kaprio J, Holm N. (2005). "Genetic susceptibility to prostate, breast, and colorectal cancer among Nordic twins." Biometrics, 2005; 61(1): 55-63.

26. Greco LRR, Coto I, Di Cosmo N, Percopo S, Maglio M, Paparo F, Gasperi V, Limongelli MG, Cotichini R, D'Agate C, Tinto N, Sacchetti L, Tosi R, Stazi MA. (2002). "The first large population based twin study of coeliac disease." Gut. 50(5): 624-628.

27. Lorenzo Bermejo J, and Hemminki K. "Risk of cancer at sites other than the breast in Swedish families eligible for BRCA1 or BRCA2 mutation testing." Ann Oncol, 2004; 15(12): 1834-41.

28. Lorenzo Bermejo J and Hemminki K. "A population-based assessment of the clustering of breast cancer in families eligible for testing of BRCA1 and BRCA2 mutations." Ann Oncol, 2005; 16(2): 322-9.

29. van Asperen C J, Brohet RM, Meijers-Heijboer EJ, Hoogerbrugge N, Verhoef S, Vasen HF, Ausems MG, Menko FH, Gomez Garcia EB, Klijn JG, Hogervorst FB, van Houwelingen JC, van't Veer LJ, Rookus MA, van Leeuwen FE, Netherlands Collaborative Group on Hereditary Breast Cancer (HEBON). "Cancer risks in BRCA2 families: estimates for sites other than breast and ovary." J Med Genet, 2005; 42(9): 711-719.

30. Kirchhoff TKN, Mitra N, Nafa K, Huang H, Palmer C, Gulati T, Wadsworth E, Donat S, Robson ME, Ellis NA, Offit K. "BRCA mutations and risk of prostate cancer in Ashkenazi Jews." Clin Cancer Res, 2004; 10(9): 2918-2921.

31. Suzuki H, Ueda T, Ichikawa T, Ito H. " Androgen receptor involvement in the progression of prostate cancer." Endocrine-related cancer, 2003; 10: 209-216.

32. Taplin ME, Bubley GJ, Ko YJ, Small EJ, Upton M, Rajeshkumar B, Balk SP. Cancer and Leukemia Group B Study 9663. "Androgen receptor mutations in androgen-in dependent prostate cancer. Cancer and Leukemia group B study, 9663." J Clinical oncology, 2003; 21: 2673-2678.

33. Febbo P, and Kantoff PW. "Androgen receptor polymorphisms and prostate cancer risk." Prostate Cancer: Biology, Genetics, and the New Therapeutics. (Chung, LWK, Isaacs, WB, Simmons, JW, editors). Totowa: Humana Press Inc, 2001: 95-109.

34. Montgomery JS, Price DK, Figg WD. "The androgen receptor gene and its influence on the development and progression of prostate cancer." Journal of Pathology, 2001; 195(2): 138-146.

35. Binnie MC, Alexander FE, Heald C, Habib FK. "Polymorphic forms of prostate specific antigen and their interaction with androgen receptor trinucleotide repeats in prostate cancer." Prostate, 2005; 63(4): 309-315.

36. Han G, Foster BA, Mistry S, Buchanan G, Harris JM, Tilley WD, Greenberg NM. Hormone status selects for spontaneous somatic androgen receptor variants that demonstrate specific ligand and cofactor dependent activities in autochthonous prostate cancer. J Biol Chem, 2001; 276(14):11204-13.

37. Edwards J, Krishna NS, Grigor KM, Bartlett JM. "Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer." Br J Cancer, 2003; 89(3): 552-6.

38. Guerini V, Sau D, Scaccianoce E, Rusmini P, Ciana P, Maggi A, Martini PGV, Katzenellenbogen BS, Martini L, Motta M, Poletti A. The androgen derivative 5a-Androstane-3 ß,17 ß-diol inhibits prostate cancer cell migration through activation of the estrogen receptor ß subtype. Cancer Res,2005; 65: 5445-53.

39. Yeh AH, Jeffery PL, Duncan RP, Herington AC, Chopin LK. Ghrelin and a novel preproghrelin isoform are highly expressed in prostate cancer and ghrelin activates mitogen-activated protein kinase in prostate cancer. Clin Cancer Res,2005;11(23):8295-303.

40. Risbridger GP, Mellor SL, McPherson SJ, Schmitt JF. The contribution of inhibins and activins to malignant prostate disease. Mol Cell Endocrinol,, 2001;180(1-2):149-53

41. Mellor SL, Ball EM, O'Connor AE, Ethier JF, Cranfield M, Schmitt JF, Phillips DJ, Groome NP, Risbridger GP. Activin betaC-subunit heterodimers provide a new mechanism of regulating activin levels in the prostate. Endocrinology,2003;144(10):4410-9.

42. Carter BS, Bova GS, Beaty TH, Steinberg GD, Childs B, Isaacs WB, Walsh PC. "Hereditary prostate cancer: epidemiologic and clinical features (review)." J Urol, 1993; 150: 797-802.

43. Lodygin D, Epanchintsev A, Menssen A, Diebold J, Hermeking H. "Functional epigenomics identifies genes frequently silenced in prostate cancer." Cancer Res, 2005; 65(10): 4218-4227.

44. Lodygin D, Hermeking H. (2005). "The role of epigenetic inactivation of 14-3-3sigma in human cancer." Cell Res, 2005; 15(4): 237-246.

45. Brothman AR, Swanson G, Maxwell TM, Cui J, Murphy KJ, Herrick J, Speights VO, Isaac J, Rohr LR. "Global hypomethylation is common in prostate cancer cells: a quantitative predictor for clinical outcome?" Cancer Genet Cytogenet, 2005; 156(1): 31-6.

46. Reis M, Pina F, Dias M, Perez M, Barros H. "Ganglionar metastization on radical prostatectomy." Acta Med Port, 2004; 17(1): 1-7.

47. Chung, L. "Stromal-epithelial interactions dictate prostate cancer androgen independent metastatic progression." Cancer Detection and Prevention, 1998; 22(Supp 1): 57.

48. Chung, LWK, Anderson NG, Neuauer BL, Cunha GR, Thompson TC, Rocco AK. Tissue interaction in prostate development: roles of sex steroids. In Prostatic Cells: Structure and Function, 1981. Alan R Liss. New York: 177-203.

49. Cunha GR & Chung LWK. Stromal-epithelial interactions. I. Introduction of prostatic phenotype of urothelium of testicular feminized (Tfm/y) mice. J Steroid Biochem, 1981; 14:1317-1321.

50. Chung, L. W. (2003). "Prostate carcinoma bone-stroma interaction and its biologic and therapeutic implications." Cancer 97(3 Suppl): 772-8.

51. Hsieh CL, Gardner TA, Miao L, Balian G, Chung LW. "Cotargeting tumor and stroma in a novel chimeric tumor model involving the growth of both human prostate cancer and bone stromal cells." Cancer Gene Ther, 2004; 11(2): 148-155.

52. Ruiz M, Pettaway C, Song R, Stoeltzing O, Ellis L, Bar-Eli M. "Activator protein 2alpha inhibits tumorigenicity and represses vascular endothelial growth factor transcription in prostate cancer cells." Cancer Res, 2004; 64(2): 631-638.

53. Wong YC, Tam NN. "Differentiation of stromal smooth muscle as a factor in prostate carcinogenesis." Differentiation, 2002; 70(9-10): 633.

54. Bayne CW, Donnelly F, Chapman K, Bollina P, Buck C, Habib F. (1998). "A novel co-culture model for benign prostatic hyperplasia expressing both isoforms of 5-reductase." J Clin Endocrinol Metab 83(1): 206-213.

55. Grant ES, Batchelor KW, Habib FK. "Androgen-independence of primary epithelial cell cultures of the prostate is associated with a down-regulation of androgen receptor gene expression." Prostate, 1996; 29: 339-349.

56. Chang SM, Chung LW. "Interaction between prostatic fibroblast and epithelial cells in culture: role of androgen." Endocrinology, 1989; 125(5): 2719-2727.

57. Condon (2005). "Seminars in Cancer." Biology 15: 132-137.

58. Bianco JJ, Handelsman DJ, Pedersen JS, Risbridger GP. "Direct response of the murine prostate gland and seminal vesicles to estradiol." Endocrinology, 2002; 143(12): 4922-4933.

59. McPherson SJ, Wang H, Jones ME, Pedersen J, Iismaa TP, Wreford N, Simpson ER, 39. 39. Risbridger GP. (2001). "Elevated androgens and prolactin in aromatase-deficient mice cause enlargement, but not malignancy, of the prostate gland." Endocrinology 142(6): 2458-4267.

60. Cunha GR, Ricke W, Thomson A, Marker PC, Risbridger G, Hayward SW, Wang YZ, Donjacour AA, Kurita T. "Hormonal, cellular, and molecular regulation of normal and neoplastic prostatic development." J Steroid Biochem Mol Biol, 2004;. 92(4): 221-236.

61. Risbridger GP, Ball EM, Wang H, Mellor SL, Peehl DM. "Re-evaluation of inhibin alpha subunit as a tumour suppressor in prostate cancer." Mol Cell Endocrinol, 2004;. 15(225 1-2): 73-76.

62. Edwards J, Bartlett JM. "The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer." BJU Int, 2005; 95(Part 1): 1319-1326.

63. Edwards J and Bartlett JM. "The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 2: Androgen-receptor cofactors and bypass pathways." BJU Int, 2005; 95(9): 1327-35.

64. Blok LJ, de Ruiter PE, Brinkmann AO. "Forskolin-induced dephosphorylation of the AR receptor impairs ligand binding." Biochemistry, 1998; 37: 3850-3857.

65. Lee HJ, Chang C. "Recent advances in androgen receptor action." Cellular Mol Life Sci, 2003; 60: 1613-1622.

66. Uzgare AR, Kaplan PJ, Greenberg NM. "Differential expression and/or activation of P38MAPK, erk1/2, and jnk during the initiation and progression of prostate cancer." Prostate, 2003; 55(2): 128-139.

67. Bakin RE, Gioeli D, Bissonette EA, Weber MJ. (2003). "Attenuation of Ras signaling restores androgen sensitivity to hormone-refractory C4-2 prostate cancer cells." Cancer Res. 63(8): 1975-1980.

68. Bakin RE, Gioeli D, Sikes RA, Bissonette EA, Weber MJ. (2003). "Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells." Cancer Res. 63(8): 1981-1989.

69. Lin HK, Hu YC, Yang L, Altuwaijri S, Chen YT, Kang HY, Chang C. "Suppression versus induction of androgen receptor functions by the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer LNCaP cells with different passage numbers." J Biol Chem, 2003; 278(51): 50902-7.

70. Ghosh PM, Malik S, Bedolla R, Kreisberg JI. "Akt in prostate cancer: possible role in androgen-independence." Curr Drug Metab, 2003; 4(6): 487-96.

71. Debes JD, Sebo TJ, Lohse CM, Murphy LM, Haugen de AL, Tindall DJ. "p300 in prostate cancer proliferation and progression." Cancer Res, 2003; 63(22): 7638-7640.

72. Chung LW, Baseman A, Assikis V, Zhau HE. "Molecular insights into prostate cancer progression: the missing link of tumor microenvironment." J Urol, 2005; 173(1): 10-20.

73. van Moorselaar RJ, Voest EE. "Angiogenesis in prostate cancer: its role in disease progression and possible therapeutic approaches." Mol Cell Endocrinol, 2002; 197(1-2): 239-250.

74. Hideshima T, Podar, K, Chauhan D, Anderson KC. " Cytokines and signal transduction." Best practice and research Clinical Haematology, 2005; 18(4): 509-524.

75. Royuela M, Ricote M, Parsons MS, Garcia-Tunon I, Paniagua R, de Miguel MP. "Immunohistochemical analysis of the IL-6 family of cytokines and their receptors in benign, hyperplasic, and malignant human prostate." J. Pathology, 2004; 202(1): 41-49.

76. Papatsoris AG, Karamouzis MV, Papavassiliou AG. "Novel insights into the implication of the IGF-1 network in prostate cancer." Trends Mol Med, 2005; 11(2): 52-5.

77. Djavan B, Waldert M, Seitz C, Marberger M. "Insulin-like growth factors and prostate cancer." World J Urology, 2001; 19: 225

78. Rubin J, Chung LW, Fan X, Zhu L, Murphy T.C,Nanes M.S, Rosen C.J "Prostate carcinoma cells that have resided in bone have an upregulated IGF-I axis." Prostate, 2003; 58: 41-49.

79. Knudsen BS, Edlund M. (2004). "Prostate cancer and the met hepatocyte growth factor receptor." Adv Cancer Research, 2004; 91: 31-67.

80. Lail-Trecker M, Gulati R, Peluso JJ. "A role for hepatocyte growth factor/scatter factor in regulating normal and neoplastic cells of reproductive tissues." J soc Gyn Invest, 1998; 5(3): 114-121.

81. Gregory CW, Fei X, Ponguta LA, He B, Bill HM, French FS, Wilson EM. "Epidermal growth factor increases coactivation of the androgen receptor in recurrent prostate cancer." J Biol Chem, 2004;279(8): 7119-30.

82. Ratan HL, Gescher A, Steward WP, Mellon JK. "ErbB receptors: possible therapeutic targets in prostate cancer?" BJU Int, 2003; 92(9): 890-5.

83. Bachman, KE and Park BH. Duel nature of TGF-beta signaling: tumor suppressor vs. tumor promoter. Curr Opin Oncol, 2005; 17(1): 49-54.

84. Bachman KE, Blair BG, Brenner K, Bardelli A Arena S, Zhou S, Hicks J, De Marzo AM, Argani P, Park BH. p21(WAF1/CIP1) mediates the growth response to TGF-beta in human epithelial cells. Cancer Biol Ther, 2004; 3(2): 221-5.

85. Yingling JM, Blanchard KM, and Sawyer JS. "Development of TGF-beta signaling inhibitors for cancer therapy." Nature Reviews, 2004; 3(12): 1011-1022.

86. De Wever O and Mareel M. "Role of tissue stroma in cancer cell invasion." J Pathol, 2003; 200(4): 429-47.

87. Slack-Davis JK, Parsons JT. "Emerging Views of Integrin Signaling:Implications for Prostate Cancer." Journal of Cellular Biochemistry, 2004; 91(1): 41-46.

88. Rovin JD, Frierson HF Jr, Ledinh W, Parsons JT, Adams RB. "Expression of Focal Adhesion kinase in Normal and Pathologyic Human prostate tissues." The Prostate, 2002; 53(2): 124-132.

89. Wu X, Gan B, YooY, Guan J-L. "FAK-mediated Src phosphorylation of Endophilin A2 inhibits endocytosis of MT1-MMP and promotes ECM degradation." Developmental Cell, 2005; 9(2): 185-196.

90. Morgia G, Falsaperla M, Malaponte G, Madonia M, Indelicato M, Travali S, Mazzarino MC. "Matrix metalloproteinases as diagnostic (MMP-13) and prognostic (MMP-2, MMP-9) markers of prostate cancer." Urol Res, 2005;. 33(1): 44-50.

91. Sauer CG, R. A., Grobholz R. (2005). "Genetic analysis of neuroendocrine tumor cells in prostatic carcinoma." Prostate. 19.

92. Wilson SR, Gallagher S, Warpeha K, Hawthorne SJ. "Amplification of MMP-2 and MMP-9 production by prostate cancer cell lines via activation of protease-activated receptors." Prostate, 2004; 60(2): 168-174.

93. Dong Z, Bonfil RD, Chinni S, Deng X, Trindade Filho JC, Bernardo M, Vaishampayan U, Che M, Sloane BF, Sheng S, Fridman R, Cher ML. (2005). "Matrix metalloproteinase activity and osteoclasts in experimental prostate cancer bone metastasis tissue." Am J Pathol, 2005; 166(4): 1173-86.

94. Huang XCS, Xu L, Liu Y, Deb DK, Platanias LC, Bergan RC. "Genistein inhibits p38 map kinase activation, matrix metalloproteinase type 2, and cell invasion in human prostate epithelial cells." Cancer Res, 2005; 65(8): 3470-3480.

95. Choong PF and Nadesapillai AP. "Urokinase plasminogen activator system: a multifunctional role in tumor progression and metastasis." Clin Orthop Relat Res, 2003;(415 Suppl): S46-58.

96. Festuccia C, Dolo V, Guerra F, Violini S, Muzi P, Pavan A, Bologna M. "Plasminogen activator system modulates invasive capacity and proliferation in prostatic tumor cells." Clin Exp Metastasis, 1998; 16(6): 513-28.

97. Gonzalez-Gronow M, Grenett HE, Weber MR, Gawdi G, Pizzo SV. "Interaction of plasminogen with dipeptidyl peptidase IV initiates a signal transduction mechanism which regulates expression of matrix metalloproteinase-9 by prostate cancer cells." Biochem J, 2001; 355(Pt 2): 397-407.

98. Gonzalez-Gronow M, Grenett HE, Gawdi G, Pizzo SV. "Angiostatin directly inhibits human prostate tumor cell invasion by blocking plasminogen binding to its cellular receptor, CD26." Exp Cell Res, 2005; 303(1): 22-31.

99. Sidenius N and Blasi F. "The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy." Cancer Metastasis Rev, 2003; 22(2-3): 205-22.

100. Margheri F, D'Alessio S, Serrati S, Pucci M, Del Rosso A, Benelli R, Ferrari N, Noonan DM, Albini A, Fibbi G, Del Rosso M. "The urokinase-type plasminogen activator, its receptor and u-PA inhibitor type-1 affect in vitro growth and invasion of Kaposi's sarcoma and capillary endothelial cells: role of HIV-Tat protein." Int J Oncol, 2005; 27(1): 223-35.

101. Xi Z, Kaern J, Davidson B, Klokk TI, Risberg B, Trope C, Saatcioglu F. "Kallikrein 4 is associated with paclitaxel resistance in ovarian cancer." Gynecol Oncol, 2004; 94(1): 80-85.

102. Haese AVV, Lilja H, Kattan MW, Rittenhouse HG, Pettersson K, Chan DW, Huland H, Sokoll LJ, Partin AW. "Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade." J Urol, 2005; 173(3): 752-756.

103. Stephan C, Jung K, Soosaipillai A, Yousef GM, Cammann H, Meyer H, Xu C, Diamandis EP. "Clinical utility of human glandular kallikrein 2 within a neural network for prostate cancer detection." BJU Int, 2005; 96(4): 521-527.

104. Steuber T, Vickers AJ, Haese A, Becker C, Pettersson K, Chun FK, Kattan MW, Eastham JA, Scardino PT, Huland H, Lilja H. (2005). "Risk assessment for biochemical recurrence prior to radical prostatectomy: Significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum." Int J Cancer, 2006; 118(5): 1234-40.

105. Clements JA, Willemsen NM, Myers SA, Dong Y. "The tissue kallikrein family of serine proteases: functional roles in human disease and potential as clinical biomarkers." Crit Rev Clin Lab Sci, 2004; 41(3): 265-312.

106. Veveris-Lowe TL, Lawrence MG, Collard RL, Bui L, Herington AC, Nicol DL, Clements JA. "Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells." Endocr Relat Cancer, 2005; 12(3): 631-643.

107. Quinn DI, Henshall SM, Sutherland RL. Molecular markers of prostate cancer outcome. Eur J Cancer, 2005; 41(6): 858-87.

108. Williams TM and Lisanti MP. "Caveolin-1 in oncogenic transformation, cancer, and metastasis." Am J Physiol Cell Physiol, 2005; 288(3): C494-506.

109. Yang G, Timme TL, Frolov A, Wheeler TM, Thompson TC. "Combined c-Myc and caveolin-1 expression in human prostate carcinoma predicts prostate carcinoma progression." Cancer, 2005; 103(6): 1186-94.

110. Epstein JI, Amin M, Boccon-Gibod L, Egevad L, Humphrey PA, Mikuz G, Newling D, Nilsson S, Sakr W, Srigley JR, Wheeler TM, Montironi R. "Prognostic factors and reporting of prostate carcinoma in radical prostatectomy and pelvic lymphadenectomy specimens." Scand J Urol Nephrol Suppl, 2005; 216: 34-63.

111. Kurek RNG, Tselis N, Konrad L, Martin T, Roeddiger S, Aumuller G, Zamboglou N, Lin DW, Tunn UW, Renneberg H. "Prognostic value of combined "triple"-reverse transcription-PCR analysis for prostate-specific antigen, human kallikrein 2, and prostate-specific membrane antigen mRNA in peripheral blood and lymph nodes of prostate cancer patients." Clin Cancer Res, 2004; 10(17): 5808-5814.

112. Lintula S, Stenman J, Bjartell A, Nordling S, Stenman UH. "Relative concentrations of hK2/PSA mRNA in benign and malignant prostatic tissue." Prostate, 2005; 63(4): 324-329.

113. Chiang CH, Hong CJ, Chang YH, Chang LS, Chen KK. "Human kallikrein-2 gene polymorphism is associated with the occurrence of prostate cancer." J Urol, 2005; 173(2): 429-432.

114. Stephenson SA, Verity K, Ashworth LK, Clements JA. "Localization of a new prostate-specific antigen-related serine protease gene, KLK4, is evidence for an expanded human kallikrein gene family cluster on chromosome 19q13.3-13.4." J Biol Chem, 1999; 274(33): 23210-4.

115. Ang J, Lijovic M, Ashman LK, Kan K, Frauman AG. “CD151 protein expression predicts the clinical outcome of low-grade primary prostate cancer better than histologic grading: a new prognostic indicator?” Cancer Epidemiol Biomarkers Prev, 2004; 13(11 Pt 1): 1717-21.

116. Downing SR, Russell PJ, Jackson P. "Alterations of p53 are common in early stage prostate cancer." Can J Urol, 2005; 10(4): 1924-1933.

117. Quinn DI, Henshall SM, Head DR, Golovsky D, Wilson JD, Brenner PC, Turner JJ, Delprado W, Finlayson JF, Stricker PD, Grygiel JJ, Sutherland RL. "Prognostic significance of p53 nuclear accumulation in localized prostate cancer treated with radical prostatectomy." Cancer Res, 2000; 60(6): 1585-94.

118. Augustin H, Hammerer PG, Graefen M, Palisaar J, Daghofer F, Huland H, Erbersdobler A. “Characterisation of biomolecular profiles in primary high-grade prostate cancer treated by radical prostatectomy.” J Cancer Res Clin Oncol, 2003; 129(11): 662-8.

119. Rubio J, Ramos D, Lopez-Guerrero JA, Iborra I, Collado A, Solsona E, Almenar S, Llombart-Bosch A. "Immunohistochemical expression of ki-67 antigen, cox-2 and bax/bcl-2 in prostate cancer; prognostic value in biopsies and radical prostatectomy specimens." Eur Urol, 2005; 48(5): 745-51.

120. Fonseca GN, Srougi M, Leite KR, Nesrallah LJ, Ortiz V."The role of HER2/neu, BCL2, p53 genes and proliferating cell nuclear protein as molecular prognostic parameters in localized prostate carcinoma." Sao Paulo Med J, 2004; 122(3): 124-7 122(3): 124-127.

121. Kaur P, Kallakury BS, Sheehan CE, Fisher HA, Kaufman RP Jr, Ross JS. "Survivin and Bcl-2 expression in prostatic adenocarcinomas." Arch Pathol Lab Med, 2004; 128(1): 39-43.

122. Tulunay O, Orhan D, Baltaci S, Gogus C, Muftuoglu YZ. “Prostatic ductal adenocarcinoma showing Bcl-2 expression.” Int J Urol.2004; Sep 11(9):805-8.

123. Rosser CJ, Reyes AO, Vakar-Lopez F, Levy LB, Kuban DA, Hoover DC, Lee AK, Pisters LL. "Bcl-2 is significantly overexpressed in localized radio-recurrent prostate carcinoma, compared with localized radio-naive prostate carcinoma." Int J Radiat Oncol Biol Phys, 2003; 56(1): 1-6.

124. Gleave M and Jansen B. "Clusterin and IGFBPs as antisense targets in prostate cancer." Ann N Y Acad Sci, 2003; 1002: 95-104.

125. Rosser CJ, Tanaka M, Pisters LL, Tanaka N, Levy LB, Hoover DC, Grossman HB, McDonnell TJ, Kuban DA, Meyn RE. (2004). "Adenoviral-mediated PTEN transgene expression sensitizes Bcl-2-expressing prostate cancer cells to radiation." Cancer Gene Ther, 2004; 11(4): 273-9.

126. Scaltriti M, Brausi M, Amorosi A, Caporali A, D'Arca D, Astancolle S, Corti A, Bettuzzi S. ""Clusterin (SGP-2, ApoJ) expression is downregulated in low- and high-grade human prostate cancer."" Int J Cancer, 2004; 108(1): 23-30.

127. Scaltriti M, Brausi M, Amorosi A, Caporali A, D'Arca D, Astancolle S, Corti A, Bettuzzi S. "Clusterin overexpression in both malignant and nonmalignant prostate epithelial cells induces cell cycle arrest and apoptosis." Br J Cancer, 2004; 91(10): 1842-1850.

128. Zhou M, Aydin H, Kanane H, Epstein JI. "How often does alpha-methylacyl-CoA-racemase contribute to resolving an atypical diagnosis on prostate needle biopsy beyond that provided by basal cell markers?" Am J Surg Pathol, 2004; 28(2): 239-243.

129. Pins MR, Fiadjoe JE, Korley F, Wong M, Rademaker AW, Jovanovic B, Yoo TK, Kozlowski JM, Raji A, Yang XJ, Lee C. "Clusterin as a possible predictor for biochemical recurrence of prostate cancer following radical prostatectomy with intermediate Gleason scores: a preliminary report." Prostate Cancer Prostatic Dis, 2004; 7(3): 243-248.

130. Zellweger T, Kiyama S, Chi K, Miyake H, Adomat H, Skov K, Gleave ME. "Overexpression of the cytoprotective protein clusterin decreases radiosensitivity in the human LNCaP prostate tumour model." BJU Int, 2003; 92(4): 463-469.

131. Caccamo AE, Scaltriti M, Caporali A, D’Arca D, Corti A, Corvetta D, Sala A, Bettuzzi S.  Ca2+ depletion induces nuclear clusterin, a novel effector of apoptosis in immortalized human prostate cells. Cell Deat Differ. 2005 12(1):101-4.

132. Bracken AP, Pasini D, Capra M, Prosperini E, Colli E, Helin K. "EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer." Embo J, 2003; 22(20): 5323-5335.

133. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, Rubin MA, Chinnaiyan AM. "The polycomb group protein EZH2 is involved in progression of prostate cancer." Nature, 2002; 419(6907): 624-9.

134. Foster CS, Falconer A, Dodson AR, Norman AR, Dennis N, Fletcher A, Southgate C, Dowe A, Dearnaley D, Jhavar S, Eeles R, Feber A, Cooper CS. (2004). "Transcription factor E2F3 overexpressed in prostate cancer independently predicts clinical outcome." Oncogene, 2004; 23(35): 5871-9.

135. Hrouda D, Nicol DL, Gardiner RA. "The role of angiogenesis in prostate development and the pathogenesis of prostate cancer." Urol Res, 2003; 30(6): 347-55.

136. Blancher C, Harris AL. "The molecular basis of the hypoxia response pathway: Tumor hypoxia as a therapy target." Cancer Metastasis Rev, 1998; 17: 187-194.

137. Chang SS. Monoclonal antibodies and prostate-specific membrane antigen. Curr Opin Investig Drugs, 2004; 5(6): 611-5.

138. Chang SS, Reuter VE, Heston WD, Bander NH, Grauer LS, Gaudin PB. "Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature." Cancer Res, 1999; 59(13): 3192-8.

139. Israeli RS, Powell CT, Fair WR, Heston WD. "Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen." Cancer Res, 1993; 53(2): 227-30.

140. Belldegrun A, Bander NH, Lerner SP, Wood Dp, Pantuck AJ. "Society of Urologic Oncology Biotechnology Forum: new approaches and targets for advanced prostate cancer." Journal of Urology, 2001; 166: 1316.

141. Leek J, Lench N, Maraj B, Bailey A, Carr IM, Andersen S, Cross J, Whelan P, MacLennan KA, Meredith DM, et al."Prostate-specific membrane antigen: evidence for the existence of a second related human gene." Br J Cancer, 1995; 72: 583-588.

142. Rinker-Schaeffer CW, Hawkins AL, Su SL, Israeli RS, Griffin CA, Isaacs JT, Heston WD. "Localization and physical mapping of the prostate-specific antigen (PSM) gene to human chromosome 11." Genomics, 1995; 30: 105-108.

143. Burger MJ, Tebay MA, Keith PA, Samaratunga HM, Clements J, Lavin MF, Gardiner RA. "Expression analysis of delta-catenin and prostate-specific membrane antigen: their potential as diagnostic markers for prostate cancer." Int J Cancer, 2002; 100(2): 228-37.

144. Landers, K. A., M. J. Burger, Tebay MA, Purdie DM, Scells B, Samaratunga H, Lavin MF, Gardiner RA.. "Use of multiple biomarkers for a molecular diagnosis of prostate cancer." Int J Cancer, 2005; 114(6): 950-6.

145. Rajasekaran AK, Anilkumar G, Christiansen JJ. "Is prostate-specific membrane antigen a multifunctional protein?" Am J Physiol Cell Physiol, 2005; 288(5): C975-81.

146. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA, Chinnaiyan AM. "Delineation of prognostic biomarkers in prostate cancer." Nature, 2001; 412(4689): 822-826.

147. Srikantan V, Valladares M, Rhim JS, Moul JW, Srivastava S. "HEPSIN inhibits cell growth/invasion in prostate cancer cells." Cancer Res, 2002; 62(23): 6812-6812.

148. Herter SPD, Aaron W, Gabriele T, Cutler G, Cao P, Bhatt AS, Choe Y, Craik CS, Walker N, Meininger D, Hoey T, Austin RJ. "Hepatocyte growth factor is a preferred in vitro substrate for human hepsin, a membrane-anchored serine protease implicated in prostate and ovarian cancers." Biochem J, 2005; 390(Pt 1): 125-136.

149. Kirchhofer DMP, Bullens S, Peale F, Bunting S. "A monoclonal antibody that inhibits mouse tissue factor function." J Thromb Haemost, 2005; May;3(5):1098-9. 3(5): 1089-1090.

150. Kirchhofer DPM, Lipari MT, Billeci K, Fan B, Moran P. (2005). "Hepsin activates pro-hepatocyte growth factor and is inhibited by hepatocyte growth factor activator inhibitor-1B (HAI-1B) and HAI-2." FEBS Lett, 2005; 259(9): 1945-1950.

151. Schalken JA. Validation of molecular targets in prostate cancer. BJU Int.2005; 96 Suppl 2:23-9.

152. Kumar-Sinha CSR, Laxman B, Tomlins SA, Harwood J, Schmitz W, Conzelmann E, Sanda MG, Wei JT, Rubin MA, Chinnaiyan AM. "Elevated alpha-methylacyl-CoA racemase enzymatic activity in prostate cancer." Am J Pathol, 2004; 164(3): 787-793.

153. Jiang Z, Li C, Fischer A, Dresser K, Woda BA. "Using an AMACR (P504S)/34betaE12/p63 cocktail for the detection of small focal prostate carcinoma in needle biopsy specimens." Am J Clin Pathol, 2005; 123(2): 231-6.

154. Mobley J A., Leav I, Zielie P, Wotkowitz C, Evans J, Lam YW, L'Esperance BS, Jiang Z, Ho SM. “Branched fatty acids in dairy and beef products markedly enhance alpha-methylacyl-CoA racemase expression in prostate cancer cells in vitro.” Cancer Epidemiol Biomarkers Prev, 2003; 12(8): 775-83.

155. Varma M, Jasani B. "Diagnostic utility of immunohistochemistry in morphologically difficult prostate cancer: review of current literature." Histopathology, 2005; 47(1): 1-16. 47(1): 1-16.

156. Zhou M, Jiang Z, Epstein JI. "Expression and diagnostic utility of alpha-methylacyl-CoA-racemase (P504S) in foamy gland and pseudohyperplastic prostate cancer." Am J Surg Pathol, 2003; 27(6): 772-8.

157. Molinie V, Fromont G, Sibony M, Vieillefond A, Vassiliu V, Cochand-Priollet B, Herve JM, Lebret T, Baglin AC. "Diagnostic utility of a p63/alpha-methyl-CoA-racemase (p504s) cocktail in atypical foci in the prostate." Mod Pathol, 2004; 17(10): 1180-90.

158. Mubiru JN, Shen-Ong GL, Valente AJ, Troyer DA. "Alternative spliced variants of the alpha-methylacyl-CoA racemase gene and their expression in prostate cancer." Gene, 2004; 327(1): 89-98.

159. Reiter RE, Gu Z, Watabe T, Thomas G, Szigeti K, Davis E, Wahl M, Nisitani S, Yamashiro J, Le Beau MM, Loda M, Witte ON. "Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer." Proc Natl Acad Sci USA, 1998; 95(11): 1735-1740.

160. Zhigang Z, Wenlu S. "Complete androgen ablation suppresses prostate stem cell antigen (PSCA) mRNA expression in human prostate carcinoma." Prostate, 2005; 65(4): 299-305.

161. Han KR, Seligson DB, Liu X, Horvath S, Shintaku PI, Thomas GV, Said JW, Reiter RE. "Prostate stem cell antigen expression is associated with gleason score, seminal vesicle invasion and capsular invasion in prostate cancer." J Urol, 2004; 171(3): 1117-21.

162. Wente MN, Jain A, Kono E, Berberat PO, Giese T, Reber HA, Friess H, Buchler MW, Reiter RE, Hines OJ. "Prostate stem cell antigen is a putative target for immunotherapy in pancreatic cancer." Pancreas, 2005; 31(2): 119-25.

163. Rodriguez JA, Li M, Yao Q, Chen C, Fisher WE. "Gene overexpression in pancreatic adenocarcinoma: diagnostic and therapeutic implications." World J Surg, 2005; 29(3): 297-305.

164. Cheng L, Reiter RE, Jin Y, Sharon H, Wieder J, Lane TF, Rao J. "Immunocytochemical analysis of prostate stem cell antigen as adjunct marker for detection of urothelial transitional cell carcinoma in voided urine specimens." J Urol, 2003; 169(6): 2094-100.

165. Matsueda S, Kobayashi K, Nonaka Y, Noguchi M, Itoh K, Harada M. "Identification of new prostate stem cell antigen-derived peptides immunogenic in HLA-A2(+) patients with hormone-refractory prostate cancer." Cancer Immunol Immunother, 2004; 53(6): 479-89.

166. Matsueda S, Yao A, Ishihara Y, Ogata R, Noguchi M, Itoh K, Harada M. "A prostate stem cell antigen-derived peptide immunogenic in HLA-A24- prostate cancer patients." Prostate, 2004; 60(3): 205-13.

167. Bussemakers MJ, van Bokhoven A, Verhaegh GW, Smit FP, Karthaus HF, Schalken JA, Devruyne FM, Ru N, Isaacs WB. “DD3: a new prostate-specific gene, highly overexpressed in prostate cancer.” Cancer Res, 1999; 59(23): 5975-9.

168. Hessels D, Klein Gunnewiek JM, van Oort I, Karthaus HF, van Leenders GJ, van Balken B, Kiemeney LA, Witjes JA, Schalken JA. “(DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer." Eur Urol, 2003; 44(1): 8-15.

169. Tinzl M, Marberger M, Horvath S, Chypre C. DD3 PCA3 analysis in urine – a new perspective for detecting prostate cancer. Eur Urol, 2004; 46: 182-7.

170. Fradet Y, Saad F, Aprikian A, Dessureault J, Elhilali M, Trudel C, Masse B, Piche L, Chypre C. “uPM3, a new molecular urine test for the detection of prostate cancer.” Urology, 2004; 64(2): 311-5.

171. Petrovics G, Liu A, Shaheduzzaman S, Furasato B, Sun C, Chen Y, Nau M, Ravindranath L, Chen Y, Dobi A, Srikantan V, Sesterhenn IA, McLeod DG, Vahey M, Moul JW, Srivastava S. "Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome." Oncogene, 2005; 24(23): 3847-3852.

172. Di Lorenzo G, De Placido S, Autorino R, De Laurentiis M, Mignogna C, D'Armiento M, Tortora G, De Rosa G, D'Armiento M, De Sio M, Bianco AR, D'Armiento FP. "Expression of biomarkers modulating prostate cancer progression: implications in the treatment of the disease." Prostate Cancer Prostatic Dis, 2005; 8(1): 54-9.

173. Ekici SCW, Duncan R, Gomez P, Civantos F, Soloway MS, Lokeshwar VB. "Comparison of the prognostic potential of hyaluronic acid, hyaluronidase (HYAL-1), CD44v6 and microvessel density for prostate cancer." Int J Cancer, 2004; 112(1): 121-129.

174. Glinsky GV, Glinskii AB, Stephenson AJ, Hoffman RM, Gerald WL. "Gene expression profiling predicts clinical outcome of prostate cancer." Journal of Clinical Investigation, 2004; 113(6): 913-923.

175. Statland BE. “Nutrition and cancer.” Clin Chem, 1992; 38(8B Pt 2): 1587-94

176. Giovannucci E, Rimm EB, Colditz GA, Stampfer MJ, Ascherio A, Chute CC, Willett WC. “A prospective study of dietary fat and risk of prostate cancer.” J Natl Cancer Inst, 1993; 85(19): 1571-9.

177. Fleshner N, Bagnell PS, Klotz L, Venkateswaran V. “Dietary fat and prostate cancer.” J Urol, 2004;171(2 Pt 2): S19-24.

178. Schuurman AG, van-den-Brandt PA, Dorant E, Brants HA, Goldbohm RA. Association of energy and fat intake with prostate carcinoma risk: results from The Netherlands Cohort Study.” Cancer, 1999; 86(6) 1019-27.

179. Zock PL, Katan MB. “Linoleic acid intake and cancer risk: a review and meta-analysis.” Am J Clin Nutr, 1998; 68(1): 142-53.

180. Kumar V. “Nutritional aspects of prostate cancer.” Urol News, 2005; 9(2): 10-13.

181. Shackelford RE, Kaufmann WK, Paules RS. “Cell cycle control, checkpoint mechanisms and genotoxic stress.” Environ Health Perspect, 1999; 107 (Suppl 1): 5-24.

182. Esposito F, RussoL, Russo T, Cimino F. “Retinoblastoma protein dephosphorylation is an early event of cellular reponse to prooxidant conditions.” FEBS Lett, 2000; 470(2): 211-5.

183. Chetcuti A, Margan SH, Russell P, Mann S, Millar DS, Clark SJ, Rogers J, Handelsman DJ, Dong Q. “Loss of annexin II heavy and light chains in rost and its precursors.” Cancer Res, 2001; 61(17): 6331-4.

184. Dannenberg AJ, Altorki NK, Boyle JO, Dang C, Howe LR, Weksler BB, Subbaramaiah K. “Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer.” Lancet Oncol, 2001; 2(9): 544-51.

185. Giovannucci E, Rimm EB, Liu Y, Stampfer MJ, Willett WC. “ A prospective study of tomato products, lycopene, and prostate cancer risk.” J Natl Cancer Inst, 1999; 91(4):317-31.

186. Giovannucci E, Rimm EB, LiuY, Stampfer MJ, Willett WC. “ A prospective study of tomato products, lycopene, and prostate cancer risk.” J Natl Cancer Inst, 2002; 94(5): 391-8.

187. Giovannucci E. “Selenium and risk of prostate cancer.” Lancet, 1998; 352(9130): 755-6.

188. Clark LC, Dalkin B, Krongrad A, Combs GF Jr, Turnbull BW, Slate EH, Witherington R, Herlong JH, Janosko E, Carpenter D, Borosso C, Falk S, Rounder J. “Decreased incidence of prostate cancer with selenium supplementation: results of a double-blind cancer prevention trial.” Br J Urol, 1998; 81(5):730-4.

189. Karunasinghe N, Ryan J, Tuckey J, Masters J, Jamieson M, Clarke L-C, Marshall JR, Ferguson LR. “DNA stability and serum selenium levels in a high-risk group for prostate cancer.” Cancer Epidemiol Biomarkers Prev, 2004; 13(3): 391-7.

190. Klein EA, Thompson IM. “Update on chemoprevention of prostate cancer.” Curr Opin Urol, 2004; 14(3):143-9.

191. Gianduzzo TR, Holmes EG, Tinggi U, Shahin M, Mactaggart P, Nicol D. “Prostatic and peripheral blood selenium levels after oral supplementation.” J Urol, 2003; 170:870-3.

192. Klein EA, Lippman SM, Thompson IM, Goodman PJ, Albanes D, Taylor PR, Coltman C. “The selenium and vitamin E cancer prevention trial.” World J Urol, 2003; 21(1): 21-7.

193. Evans S, Gillatt DA, Persad R. “Prostate cancer and race.” Urology News, 2003; 7(6):12-7.

194. Hebert JR, Hurley TG, Olendzki BC, Teas J, Ma Y, Hampl JS. “Nutritional and socioeconomic factors in relation to prostate cancer mortality: a cross-national study.” J Natl Cancer Inst, 1998; 90(21): 1637-47.

195. Lee MM, Gomez SL, Chang JS, Wey M, Wang RT, Hsing AW. “Soy and isoflavone consumption in relation to prostate cancer risk in China.” Cancer Epidemiol Biomarkers Prev, 2003; 12(7): 665-8.

196. De Vere White R, Hackman R, Soares S. “Use of a genestine-enriched compound for secondary chemoprevention of prostate cancer.” Urological Research Society abstract, 2005.

197. Dalais FS, Meliala A, Wattanapenpaiboon N, Frydenberg M, Suter DA, Thomson WK, Wahlqvist ML. “Effects of a diet rich in phytoestrogens on prostate-specific antigen and sex hormones in men diagnosed with prostate cancer.” Urology, 2004; 64(3): 510-5.

198. Schröder FH, Roobol MJ, Boeve ER, de Mutsert R, Zuijdgeest-van Leeuwen SD, Kersten I, Wildhagen MF, van Helvoort A. “Randomized, double-blind, placebo-controlled crossover study in men with prostate cancer and rising PSA: effectiveness of a dietary supplement.” Eur Urol,2005; 48(6):922-30

199. Jacobs EJ, Rodriguez C, Mondul AM, Connell CJ, Henley SJ, Calle EE, Thun MJ. “A large cohort study of aspirin and other nonsteroidal anti-inflammatory drugs and prostate cancer incidence.” J Natl Cancer Inst, 2005; 97(13): 975-80.

200. Basler JW, Piazza GA. “Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective inhibitors for prostate cancer chemoprevention.” J Urol, 2004; 171(2 Pt 2): S59-62.

201. Pruthi RS, Derksen E, Gaston K. “Cyclooxygenase-2 as a potential target in the prevention and treatment of genitourinary tumors: a review.” J Urol, 2003; 169(6): 2352-9.

202. Hussain T, Gupta S, Mukhtar H. “Cyclooxygenase-2 and prostate carcinogenesis.”

Cancer Lett, 2003; 191(2): 125-35.

203. Pan Y, Zhang JS, Gazi MH, Young CY. “The cyclooxygenase 2-specific nonsteroidal anti-inflammatory drugs celecoxib and nimesulide inhibit androgen receptor activity via induction of c-Jun in prostate cancer cells.” Cancer Epidemiol Biomarkers Prev, 2003; 12(8): 769-74.

204. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CA Jr. “The influence of finasteride on the development of prostate cancer.” N Engl J Med, 2003; 349(3): 215-24.

205. Klein EA, Tangen CM, Goodman PJ, Lippman SM, Thompson IM. “Assessing benefit and risk in the prevention of prostate cancer: the prostate cancer prevention trial revisited.” J Clin Oncol, 2005; 23: 7460-6.

206. Imamov O, Lopatkin NA, Gustafsson J-A. “Estrogen receptor ß in prostate cancer.” N Engl J Med, 2004; 351(26): 2773-4.

207. Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J. “Long-term survival among men with conservatively treated localized prostate cancer.” JAMA, 1995; 274(8): 626-31.

208. Albertsen P-C, Fryback DG, Storer BE, Kolon TF, Fine J. “The impact of co-morbidity on life expectancy among men with localized prostate cancer.” J Urol, 1996; 156(1): 127-32.

209. Parker CC, Gospodarowicz M, Warde P. “Does age influence the behaviour of localized prostate cancer?” BJU Int, 201; 87(7): 629-37.

210. Lu-Yao GL, Yao SL. “Population-based study of long-term survival in patients with clinically localised prostate cancer.” Lancet, 1997; 349(9056): 906-10.

211. Albertsen PC, Hanley JA, Fine J. “20 year outcomes following conservative management of clinically localized prostate cancer.” JAMA, 2005; 293: 2095-2101.

212. Baade PD, Steginga SK, Pinnock C & Aitken JF. “Communicating prostate cancer risk: What should we be telling our patients.” Medical Journal of Australia, 2005; 182, 472-475.

213. Melia J, Hewitson P, Austoker J. “Introduction: Review of screening for Prostate cancer.” British Journal of Urology International, 2005; 95(Supplement 3), 1-3.

214. Australian Cancer Network Working Party on Management of Localised Prostate cancer. (2002). Clinical practice guidelines: Evidence-based information and recommendations for the management of localised Prostate cancer. Canberra: National Health and Medical Research Council.

215. Green HJ, Pakenham KI, Headley BC & Gardiner RA. “Coping and health-related quality of life in men with prostate cancer randomly assigned to hormonal medication or close monitoring.” Psycho-Oncolgy, 11, 401-414.

216. O'Connor AM, Rostom A, Fiset V, Tetroe J, Entwistle V, Llewellyn-Thomas H, et al. “Decision aids for patients facing health treatment or screening decisions: Systematic review.” British Medical Journal, 1999; 319, 731-734.

217. Frosch DL, Kaplan RM. “Shared decision making in clinical medicine: Past research and future directions.” American journal of Preventative Medicine, 1999; 17(4), 285-294.

218. Elwyn G, Edwards A, Kinnersley P. “Shared decision-making in primary care: The neglected second half of the consultation.” British Journal of Primary Practice, 1999; 49, 477-482.

219. Davison BJ, Degner LF & Morgan TR. “Information and decision-making preferences of men with prostate cancer.” Oncology Nurses Forum, 1995; 22(9), 1404-1408.

220. Davison BJ, Gleave ME, Goldenberg SL, Degner LF, Hoffart D & Berkowitz J. “Assessing information and decision preferences of men with prostate cancer and their partners.” Cancer Nursing, 2002; 25(1), 42-49.

221. Barry MJ. “Involving patients in medical decisions: How can physicians do better?” Journal of the American Medical Association, 1999; 282(24), 2356-2357.

222. Braddock CH, Edwards KA, Hasenberg NM, Laidley TL & Levinson W. “Informed decison making in outpatient practice: Time to get back to basics.” Journal of the American Medical Association, 1999; 282(24), 2313-2320.

223. O'Connor AM, Stacey D, Rovner D, Holmes-Rovner M, Tetroe J, Llewellyn-Thomas H. “Decision aids for people facing health treatment or screening decisions” (Cochrane review) (Vol. Issue 3): Oxford: 2001; Update Software.

224. Australian Health Technology Advisory Committee. “Prostate cancer screening.” Canberra: Australian Government Publishing Service, 1996.

225. The Cancer Council Australia. “National cancer prevention policy 2004-2006.” NSW: The Cancer Council Australia, 2004.

226. Wilkinson S, Chodak G. “Informed consent for prostate-specific antigen screening.” Urology, 2003; 61(1), 2-4.

227. Bird S. “Discussing benefits and risks with patients psa testing.” Australian Family Physician, 2004; 33(4), 266-267.

228. Dunn IB, Kirk D. “Legal pitfalls in the diagnosis of prostate cancer.” British Journal of Urology International, 2000; 86, 304-307.

229. Carter HB. “Informed consent for prostate-specific antigen screening.” Urology, 2003; 61, 13-14.

230. Ito K, Schroder FH. “Informed consent for prostate-specific antigen-based screening - European view.” Urology, 2003; 61, 20-22.

231. Hewitson P, Austoker J. “Part 2: Patient information, informed decision making and the psycho-social impact of prostate-specific antigen testing.” British Journal of Urology International, 2005; 95(Supplement 3), 16-32.

232. Chan E, Sulmasy D. “What men should know about prostate-specfic antigen screening before giving consent.” American Journal of Medicine, 1998; 105, 266-274.

233. General Medical Council. “Seeking patients' consent: The ethical considerations.” London: 1998; General Medical Council.

234. Bratt O, Damber JE, Emanualsson M, KristoffersonU, Lundgren R, Olsson H, Gronberg H. “Risk perception, screening practice and interest in genetic testing among unaffected men in families with hereditary prostate cancer.” European Journal of Cancer, 2000; 36, 235-241.

235. Browne CT, Van der Meulen J, Newman S, Mundy AR & Emberton M. “The fear of prostate cancer in men with lower urinary tract symptoms: Should symptomatic men be screened?” British Journal of Urology, 2003; 91, 30-32.

236. Roberts RO, Rhodes T, Panser LA, Girman CJ, Chute CG, Oesterling JE, Lieber MM, Jacobsen SJ. “Natural history of prostatism: Worry and embarrassment from urinary symptoms and health care seeking behavior.” Urology, 1994; 43, 621-628.

237. Lloyd A, Hayes P, Bell PR, & Naylor AR. “The role of risk and benefit perception in informed consent for surgery.” Medical Decision Making, 2001; 21, 141-149.

238. Redelmeier DA, Rozin P & Kahneman D. “Understanding patients' decisions: Cognitive and emotional perspectives.” Journal of the American Medical Association, 1993; 270(1), 72-76.

239. Steginga SK, Occhipinti S, Gardiner RA, Yaxley J & Heathcote P. “Making decisions about treatment for localised prostate cancer.” British Journal of Urology International, 2002; 89(3), 255-260.

240. Gigerenzer G, Edwards A. “Simple tools for understanding risks: From innumeracy to insight.” British Medical Journal, 2003; 327, 741-744.

241. Gurmankin AD, Baron J, & Armstrong K. “The effect of numerical statements of risk on trust and comfort with hypothetical physician risk communication.” Medical Decision Making, 2004; 24, 265-271.

242. Paling J. “Strategies to help patients understand risks.” British Medical Journal, 2003; 327, 745-748.

243. Brawer MK. “The diagnosis of prostatic carcinoma.” Cancer, 1993; 71 (3 Suppl):899.

244. Jewitt, HJ. “Significance of the palpable prostatic nodule.” JAMA, 1956; 160:838.

245. Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, deKernion JB, Ratliff TL, Kavoussi LR, Dalkin BL. “Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men.” J Urol, 1994; 151(5):1283.

246. Ellis WJ, Chetner MP, Prestion SD, Brawer MK. “Diagnosis of prostatic carcinoma: the yield of serum prostate specific antigen, digital rectal examination, and transrectal ultrasonography.” Journal of Urology, 1994; 152(5):1520.

247. AUA Commentary. “Prostate-specific antigen best practice policy.” Oncology, 2000; 14(2):267.

248. Partin AW, Yoo J, Carter HB, Pearson JD, Chan DW, Epstein JI, Walsh PC. “The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer.” 1993; Journal of Urology, 150:110.

249. Thompson IM, Rounder JB, Teague JL, Peek M, Spence CR. “Impact of direct screening for adenocarcinoma of the prostate on stage distribution.” Journal of Urology, 1987; 137(3):424.

250. McLaughlin AP, Saltzstein SL, McCullough DL, Gittes RF. “Prostatic carcinoma: incidence and location of unsuspected lymphatic metastases.” Journal of Urology, 1976; 115(1):89.

251. Lodding P, Aus G, Bergdahl S, Frösing R, Lilja H, Pihl CG, Hugosson J. “Characteristics of screening detected prostate cancer in men 50 to 66 years old with 3 to 4 ng/ml Prostate Specific Antigen.” J Urol, 1998; 159:899-903.

252. Catalona WJ. “Prostate cancer screening.” BJU Int, 1996; 94(7):964-6.

253. Kirby R, Fitzpatrick J. “Prostate-specific antigen testing for the early detection of prostate cancer.” BJU Int, 2004; 94(7):966-7

254. Smith RA, Cokkinides V, Eyre HJ. “American Cancer Society guidelines for the early detection of cancer.” CA Cancer J Clin, 2003; 53: 27-43.

255. Fitzpatrick J. “PSA screening for prostate cancer.” Urol News, 2004; 9 (1): 6-9.

256. Donovan JL, Hamdy FC, Neal DE. “Screening for prostate cancer. The case against.” Prostate-Testing for Cancer and Treatment study group. Ann R Coll Surg Engl, 2005; 87(2): 90-1.

257. Stenman UH, Abrahamsson PA, Aus G, Lilja H, Bangma C, Hamdy FC, Boccon-Gibod L, Ekman P. “Prognostic value of serum markers for prostate cancer.” Scand J Urol Nephrol Suppl.2005; May;(216):64-81.

258. Brawer MK. “Prostate-specific antigen: current status.” CA Cancer Journal for Clinicians, 1999; 49(5):264.

259. Catalona WJ, Smith DS, Ornstein DK. “Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/ml and benign prostate examination: enhancement of specificity of PSA measurement.” JAMA, 1997; 277(18):1452.

260. Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, Scardino PT, Pearson JD. “Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update.” JAMA, 1997; 277(18):1445.

261. Brossner C, Bayer G, Madersbacher S, Kuber W, Klingler C, Pycha A. “Twelve prostate biopsies detect significant cancer volumes (> 0.5 mL).” BJU Int, 2000; 85:705-7.

262. Naughton CK, Miller DC, Mager DE, Ornstein DK, Catalona WJ. “A prospective randomized trial comparing 6 versus 12 prostate biopsy cores: impact on cancer detection.” J Urol, 2000; 164:388-92.

263. Presti JC Jr, Chang JJ, Bhargava V, Shinohara K. “The optimal systematic prostate biopsy scheme should include 8 rather than 6 biopsies: results of a prospective clinical trial.” J Urol, 2000; 163:163-7.

264. Hessels D, Verhaegh GW, Schalken JA, Witjes JA. “Applicability of biomarkers in the early diagnosis of prostate cancer.” Expert Rev Mol Diagn,2004; 4:513-26.

265. Thompson IM, Ankerst DP, Chi C, Lucia MS, Goodman PJ, Crowley JJ, Parnes HL, Coltman CA Jr. “Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower.” JAMA,2005; 294(1):66-70.

266. Pelzer AE, Tewari A, Bektic J, Berger AP, Frauscher F, Bartsch G, Horninger W. “Detection rates and biologic significance of prostate cancer with PSA less than 4.0 ng/mL: observation and clinical implications from Tyrol screening project.” Urology, 2005; 66(5):1029-33.

267. Aus G, Damber JE, Khatami A, Lilja H, Stranne J, Hugosson J. “Individualized screening interval for prostate cancer based on prostate-specific antigen level: results of a prospective, randomized, population-based study.” Arch Intern Med,2005; 165(16):1857-61.

268. Roobol MJ, Roobol DW, Schroder FH. “Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting?” (ERSPC, section Rotterdam). Urology, 2005; 65(2):343-6.

269. Oesterling JE, Jacobsen SJ, Klee GG, Pettersson K, Piironen T, Abrahamsson PA, Stenman UH, Dowel B, Lovgren T, Lilja H. “Free complexed and total serum prostate antigen: the establishment of appropriate reference ranges for their concentrations and ratios.” J Urol, 1995; 154:1090-5.

270. Fang J, Metter EJ, Landis P, Chan DW, Morrell CH, Carter HB. “Low levels of prostate-specific antigen predict long-term risk of prostate cancer: Results from the Baltimore longitudinal study of aging.” Urology, 2001; 58:411-6.

271. Carter HB, Pearson JD, Metter EJ, Brant LJ, Chan DW, Andres R, Fozard JL, Walsh PC. “Longitudinal evaluation of prostate –specific antigen levels in men and without prostate disease.” JAMA, 1992; 267:2215-20.

272. Ornstein DK, Smith DS, Humphrey PA, Catalona WJ. “The effect of prostate volume, age, total prostate specific antigen level and acute inflammation on the percentage of free serum prostate specific antigen levels in men without clinically detectable Prostate cancer.” Journal of Urology, 1998; 159(4):1234.

273. Yuan JJ, Coplen DE, Petros JA, Figenshau RS, Ratliff TL, Smith DS, Catalona WJ. “Effects of rectal examination, prostatic massage, ultrasonography, and needle biopsy of prostate-specific antigen levels.” Journal of Urology, 1992; 147(6):810.

274. Guess HA, Heyse JF, Gormley GJ, Stoner E, Oesterling JE. Effect of finasteride on serum PSA concentration in men with benign prostatic hyperplasia: results from the North American Phase III clinical trial. Urologic Clinics of North America, 1993; 20(4):627.

275. de la Taille A, Katz A, Bagiella E, Olsson CA. O'Toole KM. Rubin MA. Perineural invasion on prostate needle biopsy: an independent predictor of final pathologic stage. Urology, 1999; 54(6):1039.

276. Clements JA, Merritt T, Devoss K, Swanson C, Hamlyn L, Scells B, Rohde P, Lavin MF, Yaxley J, Gardiner RA. “Inactive free : total prostate specific antigen ratios in ejaculate from men with suspected and known prostate cancer, compared with young control men.” BJU Int.2000; Sep;86(4):453-8.

277. Savblom C, Malm J, Giwercman A, Nilsson JA, Berglund G, Lilja H. “Blood levels of free-PSA but not complex-PSA significantly correlates to prostate release of PSA in semen in young men, while blood levels of complex-PSA, but not free-PSA increase with age.” Prostate.2005; Sep 15;65(1):66-72.

278. Lilja H. “Significance of different molecular forms of serum PSA.” Urologic Clinics of North America, 1993; 20(4):681.

279. Carter, HB, Pearson, JD. “PSA velocity for the diagnosis of early prostate cancer.” Urologic Clinics of North America, 1993; 20(4):665.

280. Seaman E, Whang M, Olsson CA, Katz A, Cooner WH, Benson MC. “PSA density: role in patient evaluation and management.” Urologic Clinics of North America, 1993; 20(4):653.

281. Daneshagari F, Taylor GD, Miller GJ, Crawford ED. “Computer simulation of the probability of detecting low volume carcinoma of the prostate with six random systematic core biopsies.” Urology, 1995; 45:604-9.

282. Gore JL, Shariat SF, Miles BJ, Kadmon D, Jiang N, Wheeler TM, Slawin KM. “Optimal combinations of systematic sextant and laterally directed biopsies for the detection of prostate cancer.” J Urol, 2001; 165:1554-9.

283. Djavan B, Ravery V, Zlotta A, Dobronski P, Dobrovits M, Fakhari M, Seitz C, Susani M, Borkowski A, Boccon-Gibod L, Schulman CC, Marberger M. “Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop?” J Urol, 2001; 166:1679-83.

284. Schröder FH, Albertsen P, Boyle P, Candas B, Catalon AW, Cheng C, DeKoning HJ, Fourcade R, Hugosson J, Moul J, Perrin P, Roehrborn C, Rübben H, Stephenson R, Yamanaka H. “Early Detection and Screening for prostate cancer,” In: Prostate cancer, 3rd International Consultation Eds: L Denis, G Bartsch, S Khoury, M Murai, A Partin. Editions 21, Paris, France. 2003.

285. Vashi AR, Wojno KJ, Gillespie B, Oesterling JE. “A model for the number of cores per prostate biopsy based on patient age and prostate gland volume.” Journal of Urology, 1998; 159(3):920.

286. Bostwick DG. “Evaluating prostate needle biopsy: therapeutic and prognostic importance.” Ca: A Cancer Journal for Clinicians 1993; 47(5):297.

287. Stricker HJ, Ruddock LJ, Wan J, Belville WD. “Detection of non-palpable prostate cancer. A mathematical and laboratory model.” British Journal of Urology, 1993; 71(1):43.

288. Yanke BV, Gonen M, Scardino PT, Kattan MW. “Validation of a nomogram for predicting positive repeat biopsy for prostate cancer.” J Urol, 2005; 173 (2):421-4.

289. Enlund AL, Varenhorst E. “Morbidity of ultrasound-guided transrectal core biopsy of the prostate without prophylactic antibiotic therapy. A prospective study in 415 cases.” Br J Urol, 1997; 997; 79(5): 777-80.

290. Rodriguez, LV, Terris, MK. “Risks and complications of transrectal ultrasound guided prostate needle biopsy: a prospective study and review of the literature.” Journal of Urology, 1998; 160(6):2115.

291. Rodriguez LV, Terris MK. “Risks and complications of transrectal ultrasound.” Curr Opin Urol, 2000; 111-116.

292. Byar DP, Mostofi FK, Veteran's Administrative Cooperative Urologic Research Group. “Carcinoma of the prostate: prognostic evaluation of certain pathologic features in 208 radical prostatectomies.” Cancer 1972; 30(1):5.

293. Mostofi FK, Davis CJ, Sesterhenn IA. “Histopathology of prostate cancer.” In: Prostate Diseases. H Lepor and RK Lawson, editors. Philadelphia: WB Saunders Co. 1993; p 229.

294. Sebo TJ, Bock BJ, Cheville JC, Lohse C, Wollan P, Zincke H. “The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy.” Journal of Urology, 2000; 163(1):174.

295. Sanwick JM, Dalkin BL, Nagle RB. “Accuracy of prostate needle biopsy in predicting extracapsular tumor extension at radical retropubic prostatectomy: application in selecting patients for nerve-sparing surgery.” Urology, 1998; 52(5):814.

296. Gleason DF. “Histologic grading of prostate cancer: a perspective.” Human Pathology, 1992; 23(3):273.

297. Epstein JI, Partin AW, Sauvegout J, Walsh PC. “Prediction of progression following radical prostatectomy: a multivariate analysis of 721 men with long-term follow-up.” American Journal of Surgical Pathology, 1996; 20(2):286.

298. McNeal JE, Villers AA, Redwine EA, Freiha FS, Stamey TA. “Histologic differentiation, cancer volume, and pelvic lymph node metastasis in adenocarcinoma of the prostate.” Cancer, 1990; 66(6):1225.

299. Stamey TA, McNeal JE, Yemoto CM, Sigal BM, Johnstone IM. “Biological determinants of cancer progression in men with prostate cancer.” JAMA, 1990; 281(15):1395.

300. Haggman MJ, Macoska JA, Wojno KJ, Oesterling JE. “The relationship between prostatic intraepithelial neoplasia and prostate cancer: critical issues.” Journal of Urology, 1997; 158(1):12.

301. Bostwick DG, Pacelli A, Lopez-Beltran A. “Molecular biology of prostatic intraepithelial neoplasia.” Prostate, 1997; 29(1):117-134.

302. Bostwick DG, Brawer MK. “Prostatic intra-epithelial neoplasia and early invasion in Prostate cancer.” Cancer, 1987; 59(4):788.

303. McNeal JE, Bostwick DG. “Intraductal dysplasia: a premalignant lesion of the p Human Pathology”, 1986; 17(1):64.

304. Schlesinger C, Bostwick DG, Iczkowski KA. “High-grade prostatic intraepithelial neoplasia and atypical small acinar proliferation: predictive value for cancer in current practice” Am J Surg Pathol, 2005; 29 (9): 1201-1207.

305. Iczkowski KA, Basseler TJ, Schwob VS, Basseler IC, Kunnel BS, Orozco RE, Bostwick DG. “Diagnosis of "suspicious for malignancy" in prostate biopsies: predictive value for cancer.” Urology, 1998; 51(5):749-757.

306. Chan TY, Epstein JI. “Follow-up of atypical prostate needle biopsies suspicious for cancer.” Urology. 1999; 53(2):351-5.

307. Allen EA, Kahane H, Epstein JI. “Repeat biopsy strategies for men with atypical diagnoses on initial prostate needle biopsy.” Urology, 1998; 52:803-807.

308. Huggins C & Hodges CV. “Studies on prostatic cancer. The effect of castration, of estrogen, and of androgen injection on serum phosphates in metastatic carcinoma of the prostate.” Cancer Research, 1941; 1(1):293.

309. Huggins C, Hodges CV. “Studies of prostate cancer: II The effects of castration on advanced carcinoma.” Arch Surg, 1941; 43:209-28.

310. Small EJ, Reese DM, Vogelzang NJ. “Hormone-refractory prostate cancer: an evolving standard of care.” Seminars in Oncology, 1999; 26(5):61.

311. Bill-Axelson A, Holmberg L, Ruutu M, Haggman M, Andersson SO, Bratell S, Spangberg A, Busch C, Nordling S, Garmo H, Palmgren J, Adami HO, Norlen BJ, Johansson JE. “Radical prostatectomy versus watchful waiting in early prostate cancer.” Scandinavian-Prostate-Cancer-Group-Study-No.-4. N Engl J Med, 2005; 352(19): 1977-84.

312. Holmberg L, Bill-Axelson A, Helgesen F, Salo JO, Folmerz P, Haggman M, Andersson SO, Spangberg A, Busch C, Nordling S, Palmgren J, Adami HO, Johansson JE, Norlen BJ. “A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer.” Scandinavian-Prostatic-Cancer-Group-Study-Number-4 N Engl J Med, 2002; 347(11): 781-9.

313. Pickles T, Goldenberg SL, Steinhoff G. “Technology review: High-Intensity Focused Ultrasound for prostate cancer.” Canadian J Urol, 2005; 12:2593-7.

314. Theodorescu D. “Cancer cryotherapy: evolution and biology.” Urology, 2004; 6(suppl 4): S9-19.

315. Cohen JK. “Cryosurgery of the prostate: techniques and indications.” Urology, 2004; 6 (suppl 4): S20-6.

316. Steginga SK, Occhipinti S. “The application of the heuristic systematic processing model to treatment decision making about prostate cancer.” Medical Decision Making, 2004; 24, 573-583.

317. Harlan LC, Potosky A, Gilliland FD, Hoffman R, Albertsen PC, Hamilton AS, Eley JW, Stanford JL, Stephenson RA. “Factors associated with initial therapy for clinically localised prostate cancer: prostate cancer outcomes study.” Journal of the National Cancer Institute, 2001; 93(24), 1864-1871.

318. Post PN, Kil PJM, Hendrik AJM., Janssen-Heijnen MLG, Crommelin MA & Coebergh JWW. “Comorbidity in patients with prostate cancer and its relevance to treatment choice.” British Journal of Urology International, 1999; 84, 652-656.

319. Yan Y, Carvalhal GF, Catalona WJ & Young JD. “Primary treatment choices for men with clinically localised prostate cancer detected by screening.” Cancer, 2000; 88, 1122-1130.

320. Boehmer U, Clark JA. “Married couples perspectives on prostate cancer diagnosis and treatment decision making.” Pscho-Oncology, 2001; 10, 147-155.

321. Demark-Wahnefried W, Schildkraut JM, Iselin CE, Conlisk E, Kavee A, Aldrich TE, Lengerich EJ, Walther PJ, Paulson DF. “Treatment options, selection, and satisfaction among african american and white men with prostate carcinoma in North Carolina.” Cancer, 1998; 83, 320-330.

322. Diefenbach MA, Dorsey J, Uzzo RG, Hanks GE, Greenberg RE, Horwitz E, Newton F, Engstrom PF. “Decision-making strategies for patients with localized prostate cancer.” Seminars in Urologic Oncology, 1998; 20(1), 55-62.

323. Holmboe ES, Concato J. “Treatment decisions for localized prostate cancer.” Archives of General Internal Medicine, 2000; 15, 694-701.

324. O'Rourke ME, Germino BB. “Prostate cancer treatment decisions: A focus group exploration.” Oncology Nurses Forum, 1998; 25(1), 97-104.

325. Mazur DJ, Hickman DH. “Patient preferences for management of localized prostate cancer.” Western Journal of Medicine, 1996; 165, 26-30.

326. O'Rourke ME. “Narrowing the options: The process of deciding on prostate cancer treatment.” Cancer Investigation, 1999; 17(5), 349-359.

327. Steginga SK, Occhipinti S. “Dispositional optimism as a predictor of men's decision-related distress after localized prostate cancer”. Health Psychology (In press).

328. Folkman, S, Lazarus RS. “Coping as a mediator of emotion.” Journal of Personality and Social Psychology, 1998; 54(3), 466-475.

329. Nezu AM, Nezu CM, Friedman SH, FaddisS & Houts PS. “A problem-solving approach helping cancer patients cope.” Washington: American Psychological Association, 1998.

330. Dunn J, Steginga SK, Millichap D & Rosoman N. “A review of peer support in the context of cancer.” Journal of Psychosocial Oncology, 2003; 21(2), 55-67.

331. Coreil J, Behal R. “Man to man prostate cancer support groups.” 1999; Cancer Practice, 7(3), 122-129.

332. Manne S. “Prostate cancer support and advocacy groups: Their role for patients and family members.” Seminars in Urologic Oncology, 2002; 20(1), 45-54.

333. Steginga SK, Pinnock C, Gardner M, Gardiner RA & Dunn J. “Evaluating peer support for prostate cancer: The prostate cancer peer support inventory.” British Journal of Urology International, 2005; 95, 46-50.

334. Epstein JI, Walsh PC, Carmichael M, Brender CB. “Pathologic and clinical findings to predict tumor extent of nonpalpable (Stage T1c) prostate cancer.” JAMA, 1994; 271:368-74.

335. Bastian PJ, Mangold LA, Epstein JI, Partin AW. “Characteristics of insignificant clinical T1c prostate tumors: a contemporary analysis.” Cancer, 2004; 101:2001-5.

336. Catalona WJ, Smith DS. “Five-year tumor recurrence rates after anatomic radical retropubic prostatectomy for prostate cancer.” Journal of Urology, 1994; 152(5):1837.

337. Catalona WJ, Smith DS. “Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: intermediate-term results.” Journal of Urology 1998; 160(6):2428.

338. Walsh PC. “Radical prostatectomy for localized prostate cancer provides durable cancer control with excellent quality of life: a structured debate.” Journal of Urology, 2000, 163(6):1802.

339. Epstein JI. “Diagnostic criteria of limited adenocarcinoma of the prostate on needle biopsy.” Human Pathology, 1995; 26(2):223.

340. Oesterling JE, Martin SK, Bergstralh EJ, Lowe FC. “The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer.” JAMA, 1993; 269(1):57.

341. Walsh PC, Jewitt HJ. “Radical surgery for prostate cancer.” Cancer, 1980; 45(Suppl):1906.

342. Lu-Yao G, McLarran D, Wasson J, Wennberg JE. “An assessment of radical prostatectomy.” JAMA, 1993; 269:2633.

343. Voges GE, McNeal JE, Redwine EA, Freiha FS, Stamey TA. “Morphologic analysis of surgical margins with positive findings in prostatectomy for adenocarcinoma of the prostate.” Cancer 1992; 69:520.

344. Lerner SP, Seale-Hawkins C, Carlton CE, Scardino PT. “The risk of dying of prostate cancer in patients with clinically localized disease” Journal of Urology, 1991; 146:1040.

345. Schellhammer PF. “Radical prostatectomy: patterns of local failure and survival.” Urology, 1988; 31:191.

346. Catalona WJ, Dresner SM. “Nerve-sparing radical prostatectomy: extraprostatic tumor extension and preservation of erectile function.” Journal of Urology, 1985; 134:1149.

347. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, MacDonald D, Jin D, Shido K, Kerns S, Zhu Z, Hicklin D, Wu Y, Port JL, Altorki N, Port ER, Ruggero D, Shmelkov SV, Jensen KK, Rafii S, Lyden D. “VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche.” Nature, 2005; 438/8:820-7.

348. Khan MA, Partin AW. “Partin tables: past and present.” BJU Int, 2003; 92: 7-11.

349. Eskicorapci SY, Karabulut E, Turkeri L, Baltaci S, Cal C, Toktas G, Akpinar H, Ozer G, Sozen S, Tokuc R, Lekili M, Soylu A, Albayrak S, Sahin H, Alpar R, Ozen H. “Validation of 2001 Partin tables in Turkey: a multicenter study.” Eur Urol,2005; 47(2):185-9.

350. Augustin H, Eggert T, Wenske S, Karakiewicz PI, Palisaar J, Daghofer F, Huland H, Graefen M. “Comparison of accuracy between the Partin tables of 1997 and 2001 to predict final pathological stage in clinically localized prostate cancer.” J Urol, 2004; 171(1):177-81.

351. Steuber T, Karakiewicz PI, Augustin H, Erbersdobler A, Lange I, Haese A, Chun KH, Walz J, Graefen M, Huland H. “Transition zone cancers undermine the predictive accuracy of Partin table stage predictions.” J Urol,2005; 173(3):737-41.

352. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. “A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer.” Journal of the National Cancer Institute, 1998; 90(10):766-71.

353. Graefen M, Karakiewicz PI, Cagiannos I, Klein E, Kupelian PA, Quinn DI, Henshall SM, Grygiel JJ, Sutherland RL, Stricker PD, de Kernion J, Cangiano T, Schroder FH, Wildhagen MF, Scardino PT, Kattan MW. “Validation study of the accuracy of a postoperative nomogram for recurrence after radical prostatectomy for localized prostate cancer.” J Clin Oncol.2002; Feb 15;20(4):951-6.

354. Karakiewicz PI, Benayoun S, Kattan MW, Perrotte P, Valiquette L, Scardino PT, Cagiannos I, Heinzer H, Tanguay S, Aprikian AG, Huland H, Graefen M. J Urol.2005; Jun;173(6):1930-4.

355. Stephenson AJ, Scardino PT, Eastham JA, Bianco FJ Jr, Dotan ZA, DiBlasio CJ, Reuther A, Klein EA, Kattan MW. “Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy.” J Clin Oncol, 2005;23:7005-12.

356. Partin AW, Piantadosi S, Sanda MG, Epstein JI, Marshall FF, Mohler JL, Brendler CB, Walsh PC, Simons JW. “Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy.” Urology, 1995;45:831-838.

357. Moul JW Connelly RR, Lubeck DP, Bauer JJ, Sun L, Flanders SC, Grossfeld GD, Carroll P. “Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor databases.” J Urol, 2001; 166:1322-1327.

358. Vollmer RT, Humphrey PA. “The relative importance of anatomic and PSA factors to outcomes after radical prostatectomy for prostate cancer.” Am J Clin Pathol, 2001; 116:864-870.

359. Ohori M, Wheeler TM, Dunn JK, Stamey TA, Scardino PT. “The pathological features and prognosis of prostate cancer detectable with current diagnostic tests.” Journal of Urology, 1994; 152(5):1712.

360. Gervasi LA, Mata J, Easley JD, Wilbanks JH, Seale-Hawkins C, Carlton CE Jr, Scardino PT. “Prognostic significance of lymph node metastases in prostate cancer.” Journal of Urology 1989, 142(2):332.

361. Malavaud B, Villers A, Ravery V, Tollon C, Rischmann P, Charlet JP, Plante P, Boccon-Gibod L, Sarramon JP. “Role of preoperative positive apical biopsies in the prediction of specimen-confined prostate cancer after radical retropubic prostatectomy: a multi-institutional study.” European Urology, 2000; 37(3):281.

362. Alsikafi NF, Brendler CB. “Surgical modifications of radical retropubic prostatectomy to decrease incidence of positive surgical margins.” Journal of Urology, 1998; 159(4):1281.

363. Stamey TA, Villers AA, McNeal JE, Link PC, Freiha FS. “Positive surgical margins at radical prostatectomy: importance of the apical dissection.” Journal of Urology 1990; 143(3):1143.

364. D'Amico AV, Chen MH, Roehl KA, Catalona WJ. “Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy.” N Engl J Med, 2004; 351(2): 125-35.

365. Gao CL, Maheshwari S, Dean RC, Tatum L, Mooneyhan R, Connelly RR, McLeod DG, Srivastava S, Moul JW. “Blinded evaluation of reverse transcriptase-polymerase chain reaction prostate-specific antigen peripheral blood assay for molecular staging of prostate cancer.” Urology 1999; 53(4):714.

366. Ellis WJ, Vessella RL, Corey E, Arfman EW, Oswin MM, Melchior S, Lange PH. “The value of a reverse transcriptase polymerase chain reaction assay in preoperative staging and follow-up of patients with prostate cancer.” Journal of Urology, 1998; 159(4):1134.

367. Sokoloff MH, Tso CL, Kaboo R, Nelson S, Ko J, Dorey F, Figlin RA, Pang S, deKernion J, Belldegrun A. “Quantitative polymerase chain reaction does not improve prostate cancer staging: a clinical-pathologic-molecular analysis of 121 patients.” Journal of Urology, 1996; 156(5):1560.

368. Oesterling JE, Brendler CB, Epstein JI, Kimball AW Jr, Walsh PC. “Correlation of clinical stage, serum prostatic acid phosphatase, and preoperative Gleason grade with final pathological stage in 275 patients with clinically localized adenocarcinoma of the prostate.” Journal of Urology, 1987; 138(1):92.

369. McNeal JE. “Cancer volume and site of origin of adenocarcinoma of the prostate: relationship to local and distant spread.” Human Pathology, 1992; 23(2):258.

370. Stamey TA, Freiha FS, McNeal JE, Redwine EA, Whittemore AS, Schmid HP. “Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer.” Cancer 1993; 71(3 Suppl):933.

371. Goto Y, Ohari M, Scardino PT. “Use of systemic biopsy results to predict pathologic stage in patients with clinically localized prostate cancer: a preliminary report.” International Journal of Urology 1998; 5(3):337.

372. Brassell SA, Rosner IL, McLeod DG. “Update on magnetic resonance imaging, ProstaScint and novel imaging in prostate cancer.” Curr Opin Urol, 2005; 15: 163-6.

373. Crook J, McLean M, Catton C, Yeung I, Tsihlias J, Pintilie M. “Factors influencing risk of acute urinary retention after TRUS-guided permanent prostate seed implantation.” Int J Radiat Oncol Biol Phys 2002; 52, 453-60.

374. Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Gil T, Collette L, Pierart M. “Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin.” N Engl J Med, 1997; 337(5): 295-300.

375. Bolla M, Collette L, Blank L, Warde P, Dubois J B, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Mattelaer J, Lopez-Torecilla J, Pfeffer JR, Lino-Cutajar C, Zurlo A, Pierart M. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet, 2002; 360(9327): 103-6.

376. Lamb DS, Denham JW, Mameghan H, Joseph D, Turner S, Matthews J, Franklin I, Atkinson C, North J, Poulsen M, Kovacev O, Robertson R, Francis L, Christie D, Spry NA, Tai KH, Wynne C, Duchesne G. Acceptability of short term neo-adjuvant androgen deprivation in patients with locally advanced prostate cancer. Radiother Oncol, 2003; 68(3): 255-67.

377. Pilepich MV, Winter K, Lawton C A, Krisch RE, Wolkov HB, Movsas B, Hug EB, Asbell SO, Grignon D. “Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31.” Int J Radiat Oncol Biol Phys, 2005; 61(5): 1285-90.

378. Van den Ouden D, Hop WC, Schroder FH. “Progression in a survival of patients with locally advanced prostate cancer (T3) treated with radical prostatectomy as monotherapy.” Journal of Urology, 1998; 160(4):1392-7.

379. Potosky A, Davis WW, Hoffman RM, Stanford JL, Stephenson RA, Penson DF., et al. “Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: The prostate cancer outcomes study.” Journal of the National Cancer Institute, 2004; 96(18), 1358-1367.

380. Schover LR, Fouladi RT, Warneke CL, Neese L, Klein EA, Zippe C, Kupelian PA. “Defining sexual outcomes after treatment for localized prostate cancer.” Cancer, 2002; 95, 1773-1785.

381. Steginga SK, Occhipinti S, Dunn J, Gardiner RA, Heathcote P, Yaxley J. “The supportive care needs of men with prostate cancer.” Psycho-Oncology, 2001; 10, 66-75.

382. Steginga SK, Occhipinti S, Gardiner RA, Yaxley J, & Heathcote P. “A prospective study of men's psychological and decision-related adjustment after treatment for localized prostate cancer.” Urology, 2004; 63, 751-756.

383. Savoie M, Kim SS & Soloway MS. “A prospective study measuring penile length in men treated with radical prostatectomy for prostate cancer.” The Journal of Urology, 2002; 169, 1462-1464.

384. Barnas JL, Pierpaoli S, Ladd P, Valenzuela R, Aviv N, Parker M, Waters WB, Flanigan RC, Mulhall JP. “The prevalence and nature of orgasmic dysfunction after radical prostatectomy.” British Journal of Urology International, 2004; 94, 603-605.

385. Bokhour BG, Clark JA, Thomas S, Silliman RA, Talcott JA. “Sexuality after treatment for early prostate cancer. Exploring the meanings of "erectile dysfunction". Journal of General Internal 2001; Medicine, 16, 649-655.

386. Gontero P, Fontana F, Bagnasacco A, Panella M, Kocjancic E, Pretti G, Frea B. “Is there an optimal time for intracavernous prostaglandin e1 rehabilitation following nonnerve sparing radical prostatectomy? Results from a hemodynamic prospective study.” The Journal of Urology, 2003; 169, 2166-2169.

387. Montorsi F, Guazzoni G, Strambi LF, Da Pozzo LF, Nava L, Barbieri L, Rigatti P, Pizzini G, Miani A. “Recovery of spontaneous erectile function after nerve sparing radical retropubic prostatectomy with and without early intracavernous injection sof alprostadil: Results of a prospective, randomised trial.” The Journal of Urology, 1997; 158(4), 1408-1410.

388. Schover LR, Fouladi RT, Warneke CL, Neese L, Klein EA, Zippe C, Kupelian PA. “Seeking help for erectile dysfunction after treatment for prostate cancer.” Archives of Sexual Behavior, 2004; 33(5), 443-454.

389. Stephenson RA, Mori M, Hsieh YC, Beer TM, Stanford JL, Gilliland FD, Hoffman RM, Potosky AL. “Treatment of erectile dysfunction following therapy for clinically localized and End Results Prostate Cancer Outcomes Study.” J Urol, 2005; 174: 646-50.

390. Davison BJ, Keyes M, Elliott S, Berkowitz J, Goldenberg SL. “Preferences for sexual information resources in patients treated for early stage prostate cancer with either radical prostatectomy or brachytherapy.” British Journal of Urology International, 2004; 93, 965-969.

391. Neese L, Schover LR, Klein EA, Zippe C, Kupelian PA. “Finding help for sexual problems after prostate cancer treatment: A phone survey of men's and women's perspectives.” Psycho-Oncology, 2003; 12, 463-473.

392. Canada AL, Neese L, Sui D & Schover LR. “A pilot intervention to enhance sexual rehabilitation for couples after treatment for localized prostate cancer”. Cancer. (In press).

393. Walsh, PC. “Radical retropubic prostatectomy with reduced morbidity: an anatomic approach.” NCI Monographs, 1988; 7:133.

394. Litwin MS, Hays RD, Fink A, Ganz PA, Leake B, Leach GE, Brook RH. “Quality-of-life outcomes in men treated for localized prostate cancer” JAMA, 1995; 273(2):129.

395. Litwin MS, McGuigan KA, Shpall AI, Dhanani N. “Recovery of health related quality of life in the year after radical prostatectomy: early experience.” Journal of Urology, 1999; 161(2):515.

396. Reiner WG, Walsh PC. “An anatomical approach to the surgical management of the dorsal vein and Santorinin's plexus during radical retropubic surgery.” 1979; Journal of Urology, 121(1):198.

397. Walsh PC, Lepor H, Eggleston JC. “Radical prostatectomy with preservation of sexual function: anatomical and pathological considerations.” Prostate, 1983; 4:473.

398. Graefen M, Walz J, Chun KH, Schlomm T, Haese A, Huland H. „Reasonable delay of surgical treatment in men with localized prostate cancer--impact on prognosis?” Eur Urol.2005; Jun;47(6):756-60.

399. Boorjian SA, Bianco FJ Jr, Scardino PT, Eastham JA. “Does the time from biopsy to surgery affect biochemical recurrence after radical prostatectomy?” BJU Int, 2005; 96:773-6.

400. Worwag E, Chodak GW. “Overnight hospitalization after radical prostatectomy: the impact of two clinical pathways on patient satisfaction, length of hospitalization, and morbidity.” Anesthesia & Analgesia, 1998; 87(1):62.

401. Shir Y, Frank SM, Brendler CB, Raja SN. “Postoperative morbidity is similar in patients anesthetized with epidural and general anesthesia for radical prostatectomy.” Urology, 1994; 44(2):232.

402. Shir Y, Raja SN, Frank SM, Brendler CB. “Intraoperative blood loss during radical retropubic prostatectomy: epidural versus general anesthesia.” Urology, 1995; 45(6):993.

403. Helgason AR, Adolfsson J, Dickman P, Arver S, Fredrikson M, Gothberg M, Steineck G. “Sexual desire, erection, orgasm and ejaculatory functions and their importance to elderly Swedish men: a population-based study.” Age Ageing, 1996; 25(4): 285-91.

404. Blanker MH, Bosch JL, Groeneveld FP, Bohnen AM, Prins A, Thomas S, Hop WC. “Erectile and ejaculatory dysfunction in a community-based sample of men 50 to 78 years old: prevalence, concern, and relation to sexual activity.” Urology, 2001; 57(4): 763-8.

405. Singer PA, Tasch ES, Stocking C, Rubin S, Siegler M, Weichselbaum R.„Sex or survival: trade-offs between quality and quantity of life.” Journal of Clinical Oncology 1991; 9(2):328.

406. Mantz CA, Nautiyal J, Awan A, Kopnick M, Ray P, Kandel G, Niederberger C, Ignacio L, Dawson E, Fields R, Weichselbaum R, Vijayakumar S.« Potency preservation following conformal radiotherapy for localized prostate cancer: impact of neoadjuvant androgen blockade, treatment technique, and patient-related factors.” Cancer Journal From Scientific American 1999; 5(4):230.

407. Krupski T, Petroni GR, Bissonette EA, Theodorescu D. “Quality-of-life comparison of radical prostatectomy and interstitial brachytherapy in the treatment of clinically localized prostate cancer.” Urology, 2000; 55(5);736.

408. Jonler M, Messing EM, Rhodes PR, Bruskewitz RC. “Sequelae of radical prostatectomy.” British Journal of Urology, 1994; 74:352.

409. Fowler FJ Jr, Barry MJ, Lu-Yao G, Roman A, Wasson J, Wennberg JE. “Patient-reported complications and follow-up treatment after radical prostatectomy. The National Medicare Experience: 1988-1990” (updated June 1993). Urology, 1993; 42:622.

410. Heathcote PS, Mactaggart PN, Boston RJ, James AN, Thompson LC, Nicol DL. “Health-related quality of life in Australian men remaining disease-free after radical prostatectomy.” Medical J of Australia, 1998; 168:483.

411. Ojdeby G, Claezon A, Brekkan E, Haggman M, Norlen BJ. “Urinary incontinence and sexual impotence after radical prostatectomy.” Scandinavian Journal of Urology and Nephrology, 1996; 30:473.

412. Gaylis FD, Friedel WE, Armas OA. “Radical retropubic prostatectomy outcomes at a community hospital.” Journal of Urology, 1998; 159:167.

413. Talcott JA, Manola J, Clark JA, Kaplan I, Beard CJ, Mitchell SP, Chen RC, O'Leary MP, Kantoff PW, D'Amico AV. “Time course and predictors of symptoms after primary prostate cancer therapy.” J Clin Oncol 2003; 21, 3979-86.

414. Sole-Balcells F, Villavicencio H, Ortiz A. “Postsurgical management of the patient undergoing radical prostatectomy.” British Journal of Urology, 1992; 70(1 Suppl):43.

415. Davidson PJ, van den Ouden D, Schroeder FH. “Radical prostatectomy: prospective assessment of mortality and morbidity.” European Urology, 1996; 29(2):168.

416. Ritchie AW, James K, deKernion JB. “Early post-operative morbidity of total prostatectomy.” British Journal of Urology, 1989; 64(3):511.

417. Catalona WJ, Carvalhal GF, Mager DE, Smith DS. “Potency, continence and complication rates in 1,870 consecutive radical retropubic prostatectomies.” Journal of Urology, 1999; 162(2):433.

418 Quinlan DM, Epstein JI, Carter BS, Walsh PC. “Sexual function following radical prostatectomy: influence of preservation of neurovascular bundles.” Journal of Urology, 1991; 145(3):998.

419. Leandri P, Rossignol G, Gautier JR, Ramon J. “Radical retropubic prostatectomy: morbidity and quality of life. Experience with 620 consecutive cases.” Journal of Urology, 1992; 147(3):883.

420. Noh C, Kshirsagar A, Mohler JL. “Outcomes after radical retropubic prostatectomy.” Urology, 2003; 61(2): 412-6.

421. Walsh PC, Marschke P, Ricker D, Burnett AL. “Patient-reported urinary continence and sexual function after anatomic radical prostatectomy.” Urology, 2000; 55(1):58.

422. Link RE, Su LM, Sullivan W, Bhayani SB, Pavlovich CP. “Health related quality of life before and after laparoscopic radical prostatectomy.” J Urol, 2005; 173(1): 175-9; discussion 179.

423. Epstein JI. “Evaluation of radical prostatectomy capsular margins of resection. The significance of margins designated as negative, closely approaching, and positive.” American Journal of Surgical Pathology, 1995; 14(7):626.

424. Epstein JI, Pizov G, Walsh PC. “Correlation of pathologic findings with progression after radical retropubic prostatectomy.” Cancer, 1993; 71(11):3582.

425. Rosen MA, Goldstone L, Lapin S, Wheeler T, Scardino PT. “Frequency and location of extracapsular extension of positive surgical margins in radical prostatectomy specimens.” Journal of Urology, 1992; 142(2):331.

426. Roumeguere T, Bollens R, Vanden-Bossche M, Rochet D, Bialek D, Hoffman P, Quackels T, Damoun A, Wespes E, Schulman CC, Zlotta AR. “Radical prostatectomy: a prospective comparison of oncological and functional results between open and laparoscopic approaches.” World J Urol, 2003; 20(6): 360-6.

427. Chuang MS, O'Connor RC, Laven BA, Orvieto MA, Brendler CB. “Early release of the neurovascular bundles and optical loupe magnification lead to improved and earlier return of potency following radical retropubic prostatectomy.” J Urol, 2005; 173(2): 537-9.

428. Porpiglia F, Ragni F, Terrone C, Renard J, Musso F, Grande S, Cracco C, Ghignone G, Scarpa RM. “Is laparoscopic unilateral sural nerve grafting during radical prostatectomy effective in retaining sexual potency?” BJU Int, 2005; 95(9): 1267-71.

429. Kim ED, Scardino PT, Hampel O, Mills NL, Wheeler TM, Nath RK. “Interposition of sural nerve restores function of cavernous nerves resected during radical prostatectomy.” J Urol, 1999; 61(1): 188-92.

430. Scardino PT, Kim ED. “Rationale for and results of nerve grafting during radical prostatectomy.” Urology, 2001; 57(6): 1016-9.

431. Kim ED, Nath R, Slawin KM, Kadmon D, Miles BJ, Scardino PT. “Bilateral nerve grafting during radical retropubic prostatectomy: extended follow-up.” Urology, 2001; 58(6): 983-7.

432. Joseph JV, Vincente I, Madeb R, Erturk E, Patel, HRH. “Robot-assisted vs laparoscopic radical proatatectomy: are there any differences?” BJU Int, 2005; 96:39-42

433. Webster TM, Herrell SD, Chang SS, Cookson MS, Baumgartner RG, Anderson LW, Smith JA Jr. “Robotic assisted laparoscopic radical prostatectomy versus retropubic radical prostatectomy: a prospective assessment of postoperative pain.” J Urol.2005; Sep, 174(3):912-4; discussion 914.

434. Ahlering TE, Eichel L, Edwards RA, Lee DI, Skarecky DW. “Robotic radical prostatectomy: a technique to reduce pT2 positive margins.” Urology, 2004;64(6): 1224-8.

435. Touijer K, Kuroiwa K, Saranchuk JW, Hassen WA, Trabulsi EJ, Reuter VE, Guillonneau B. “Quality improvement in laparoscopic radical prostatectomy for pT2 prostate cancer: impact of video documentation review on positive surgical margin.” J Urol, 2005; 173(3): 765-8.

436. Costello AJ, Haxhimolla H, Crowe H, Peters, JS. “Installation of telerobotic surgery and initial experience with telerobotic radical prostatectomy.” BJU Int, 2005; 96:34-8.

437. Pienta K, Redman B, Hussain M. “Phase II study of estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate.” Journal of Clinical Oncology, 1994; 12(10):2005.

438. Chung LWK. “Implications of stromal-epithelial interaction in human prostate cancer growth, progression and differentiation.” Semin Cancer Biol, 1993; 4: 183-192.

439. Labrie F, Candas B, Cusan L, Gomez JL, Diamond P, Suburu R, Lemay M. “Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostate-specific antigen.” Urology, 1996; 47(2):212.

440. Arai Y, Kanamaru H, Yoshimura K, Okubo K, Kamoto T, Yoshida O. “Incidence of lymph node metastasis and its impact on long-term prognosis in clinically localized prostate cancer.” International Journal of Urology, 1998; 5(5):459-65.

441. Ekman P. “Predicting pelvic lymph node involvement in patients with localized prostate cancer.” European Urology, 1997; 32(Suppl 3):60-4.

442. Danella JF, deKernion JB, Smith RB, Steckel J. “The contemporary incidence of lymph node metastases in prostate cancer: implications for laparoscopic lymph node dissection.” Journal of Urology, 1993; 149(6):1488-91.

443. Alagiri M, Colton MD, Seidmon EJ, Greenberg RE, Hanno PM. “The staging of pelvic lymphadenectomy: implications as an adjunctive procedure for clinically localized prostate cancer.” British Journal of Urology, 1997; 80(2):243-6.

444. Partin AW, Pearson JD, Landis PK, Carter HB, Pound CR, Clemens JQ, Epstein JI, Walsh PC. “Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastasis.” Urology, 1994; 43(3):649.

445. Messing EM, Manola J, Sarodsy M, Wilding G, Crawford ED, Truno D. “Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenopathy in men with node positive prostate cancer.” New Engl J Med, 1999; 341(24):1781.

446. Steiner MS, Marshall FF. “Mini-laparotomy staging pelvic lymphadenectomy (minilap). Alternative to standard and laparoscopic pelvic lymphadenectomy.” Urology, 1993; 41(3):201.

447. Wagner JR, Russo P. “Urologic complications of major pelvic surgery.” Seminars in Surgical Oncology, 2000; 18(3):216.

448. Heinzer H, Graefen M, Noldus J, Hammerer P, Huland H. “Early complication of anatomical radical retropubic prostatectomy: lessons from a single-center experience.” Urologia Internationalis, 1997; 59(1):30.

449. Paul DP, Loening SA, Narayana AS, Culp DA. “Morbidity from pelvic lymphadenectomy in staging carcinoma of the prostate.” Journal of Urology, 1983; 129(3):1141.

450. McCullough DL, McLaughlin AP, Gittes RF. “Morbidity of pelvic lymphadenectomy and radical prostatectomy for prostatic cancer.” Journal of Urology, 1977; 117(2):206.

451. Sibert L, Descargues G, Scotte M, Planet M, Thoumas D, Annoot M, Boillot B, Grise P. “Laparoscopic drainage of a lymphocele after radical prostatectomy.” Annales d'Urologie, 1994; 28(4):202.

452. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. “Natural history of progression after PSA elevation following radical prostatectomy.” JAMA, 1999; 281(17): 1591-7.

453. Krongrad A, Lai H, Lai S. “Survival after radical prostatectomy.” JAMA, 1997; 278(1):44-46.

454. Tefilli MV, Gheiler EL, Tiguert R, Banerjee M, Sakr W, Grignon D, Wood DP Jr, Pontes JE. “Role of radical prostatectomy in patients with prostate cancer of high Gleason score.” Prostate, 1999; 39(1):60.

455. Kupelian P, Katcher J, Levin H, Zippe C, Klein E. “Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer.” Urology, 1996; 48(2):249.

456. Gerber GS, Thisted RA, Scardino PT, Frohmuller HG, Schroeder FH, Paulson DF, Middleton AW Jr, Rukstalis DB, Smith JA Jr, Schellhammer PF, Ohori M, Chodak GW. “Results of radical prostatectomy in men with clinically localized prostate cancer.” JAMA 1996; 276(8):615.

457. Blute ML, Bostwick DG, Bergstralh EJ, Slezak JM, Martin SK, Amling CL, Zincke H. “Anatomic site-specific positive margins in organ-confined prostate cancer and its impact on outcome after radical prostatectomy.” Urology, 1997; 50(5):733.

458. Ohori M, Wheeler TM, Kattan MW, Goto Y, Scardino PT. “Prognostic significance of positive surgical margins in radical prostatectomy specimens.” J Urol, 1995; 154:1818-24.

459. Rigaud J, Tiguert R, Decobert M, Hovington H, Latulippe E, Laverdiere J, Larue H, Lacombe L, Fradet Y. “Expression of p21 cell cycle protein is an independent predictor of response to salvage radiotherapy after radical prostatectomy.” Prostate, 2004; 58:269-76.

460. Fizazi K, Martinez LA, Sikes CR, Johnston DA, Stephens LC, McDonnell TJ, Logothetis CJ, Trapman J, Pisters LL, Ordonez NG, Troncoso P, Navone NM. “The association of p21 (WAF-1/CIP1)) with progression to androgen-independent prostate cancer.” Clin Cancer Res, 2002; 8:775-81.

461. Bauer JJ, Sesterhenn IA, Mostofi KF, McLeod DG, Srivastava S, Moul JW. “p53 nuclear protein expression is an independent prognostic marker in clinically localized prostate cancer patients undergoing radical prostatectomy.” Clin Cancer Res,1995; 1:1295-300.

462. Halvorsen OJ, Haukaas SA, Akslen LA. “Combined loss of PTEN and p27 expression is associated with tumor cell proliferation by Ki-67 and increased risk of recurrent disease in localized prostate cancer.” Clin Cancer Res, 2003; 9:1474-9.

463. Fradet V, Lessard L, Bégin LR, Karakeiwicz P, Masson A-M M, Saad F. “Nuclear Factor-?B nuclear localization is predictive of biochemical recurrence in patients with positive margin prostate cancer.” Clin Cancer Res, 2004; 10: 8460-4.

464. Walsh PC, Partin AW, Epstein JI. “Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years.” Journal of Urology, 1994; 152(5 Pt 2):1831.

465. Pound CR, Partin AW, Epstein JI. “Prostate-specific antigen after anatomic radical retropubic prostatectomy: patterns of recurrence and cancer control.” Urologic Clinics of North America, 1997; 242(2):395.

466. Partin AW, Pound CR, Clemens JQ, Epstein JI, Walsh PC. “Serum PSA after anatomic radical prostatectomy.” “The Johns Hopkins experience after 10 years.” Urol Clin North Am, 1993; 20(4): 713-25.

467. Paulson DF. “Impact of radical prostatectomy in the management of clinically localized disease.” J Urol 1994; 152:1826-1830.

468. Amling CL, Bergstralh EJ, Blute ML, Slezak JM, Zincke H. “Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point?” J Urol, 2001; 165:1146-1151.

469. Freedland SJ, Sutter ME, Dorey F, Aronson WJ. “Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen.” Urology, 2003; 61(2): 365-9.

470. Jhaveri FM, Zippe CD, Klein EA, Kupelian PA. “Biochemical failure does not predict overall survival after radical prostatectomy for localized prostate cancer: 10-year results.” Urology, 1999; 54(5): 884-90.

471. Prostate Cancer End Points Workshop Presentations, 2004.

472. Albertsen PC, Hanley JA, Penson DF, Fine J. “Validation of increasing prostate specific antigen as a predictor of prostate cancer death after treatment of localized prostate cancer with surgery or radiation.” J Urol, 2004; 171:2221-5

473. D'Amico AV, Moul JW, Carroll PR, Sun L, Lubeck D, Chen MH. “Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy.” J Natl Cancer Inst, 2003; 95(18): 1376-83.

474. Shelfo SW, Obek C, Soloway MS. “Update on bladder neck preservation during radical retropubic prostatectomy: impact on pathologic outcome, anastomotic sutures, and continence.” Urology, 1998; 51(1):73.

475. Lowe BA. “Preservation of the anterior urethral ligamentous attachments in maintaining post-prostatectomy urinary continence.” Journal of Urology 1997; 158(6):2137.

476. Goluboff ET, Saidi JA, Mazer S. “Urinary continence after radical prostatectomy: the Columbia experience.” Journal of Urology, 1998; 159(4):1276.

477. Kaye KW, Creed KE, Wilson GJ, D'Antuono M, Dawkins HJ. “Urinary continence after radical retropubic prostatectomy. Analysis and synthesis of contributing factors: a unified concept.” British Journal of Urology, 1997; 80(3):444.

478. Seaman EK & Benson MC. “Improved continence with tubularized bladder neck reconstruction following radical retropubic prostatectomy.” Urology 1996; 47(4):532.

479. Poore RE, McCullough DL, Jarow JP. “Puboprostatic ligament sparing improves urinary continence after radical retropubic prostatectomy.” Urology, 1998; 51(1):67.

480. Moul JW. “Pelvic muscle rehabilitation in males following prostatectomy.” Urologic Nursing, 1998; 18(4):296.

481. Montague DK, Angermeier KW. “Post-prostatectomy urinary incontinence: the case for artificial urinary sphincter implantation.” Urology, 2000; 55(1):2.

482. Bahnson RR, Catalona WJ. “Complications of radical retropubic prostatectomy.” In: Complications of Urologic Surgery: Prevention and Management (second edition); RB Smith and RM Ehrlich, editors. Philadelphia: WB Saunders Co, 1990; p.386.

483. Meulen T, Zambon JV, Janknegt RA. “Treatment of anastomotic strictures and urinary incontinence after radical prostatectomy with urolume wallstent and AMS 800 artificial sphincter.” Journal of Endourology, 1999; 13(7):517.

484. Mulcahy JJ. “Erectile function after radical prostatectomy.” Seminars in Urologic Oncology, 2000; 18(1):71.

485. Raina R, Agarwal A, Zippe CD. “Management of erectile dysfunction after radical prostatectomy.” Urology, 2005; 66:923-9.

486. Ohebshalom M, Parker M, Guhring P, Mulhall JP. “The efficacy of sildenafil citrate following radiation therpay for prostate cancer: temporal considerations.” J Urol, 2005; 174: 258-62.

487. Leibovitch I, Foster RS, Wass JL, Rowland RG, Bihrle R, Little JS Jr, Kopecky KK, Donohue JP.“Color Doppler flow imaging for deep vein thrombosis screening in patients undergoing pelvic lymphadenopathy and radical retropubic prostatectomy for prostatic cancer.” Journal of Urology 1995; 153(6):1866.

488. Choo, R., G. Hruby, J. Hong, E. Hong, G. DeBoer, C. Danjoux, G. Morton, L. Klotz, E. Bhak, and A. Flavin. Positive resection margin and/or pathologic T3 adenocarcinoma of prostate with undetectable postoperative prostate-specific antigen after radical prostatectomy: to irradiate or not? Int J Radiat Oncol Biol Phys, 2002 52:674-80.

489. Schild, S. E., W. W. Wong, G. L. Grado, M. Y. Halyard, D. E. Novicki, S. K. Swanson, T. R. Larson, and R. G. Ferrigni. The result of radical retropubic prostatectomy and adjuvant therapy for pathologic stage C prostate cancer. Int J Radiat Oncol Biol Phys, 1996 34:535-41.

490. Syndikus, I., T. Pickles, E. Kostashuk, and L. D. Sullivan. Postoperative radiotherapy for stage pT3 carcinoma of the prostate: improved local control. J Urol, 1996 155:1983-6.

491. Vargas, C., L. L. Kestin, D. W. Weed, D. Krauss, F. A. Vicini, and A. A. Martinez. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features. Int J Radiat Oncol Biol Phys, 2005 61:714-24.

492. Zietman, A. L., J. J. Coen, W. U. Shipley, and A. F. Althausen. Adjuvant irradiation after radical prostatectomy for adenocarcinoma of prostate: analysis of freedom from PSA failure. Urology, 1993 42:292-8; discussion 298-9.

493. Leibovich, B. C., D. E. Engen, D. E. Patterson, T. M. Pisansky, E. E. Alexander, M. L. Blute, E. J. Bergstralh, and H. Zincke. Benefit of adjuvant radiation therapy for localized prostate cancer with a positive surgical margin. J Urol, 2000 163:1178-82.

494. Valicenti, R. K., L. G. Gomella, M. Ismail, S. E. Strup, S. G. Mulholland, A. P. Dicker, R. O. Petersen, and C. J. Newschaffer. The efficacy of early adjuvant radiation therapy for pT3N0 prostate cancer: a matched-pair analysis. Int J Radiat Oncol Biol Phys, 1999 45:53-8.

495. Bolla, M., H. van Poppel, L. Collette, P. van Cangh, K. Vekemans, L. Da Pozzo, T. M. de Reijke, A. Verbaeys, J. F. Bosset, R. van Velthoven, J. M. Marechal, P. Scalliet, K. Haustermans, and M. Pierart. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet, 2005 366:572-8.

496. Van Cangh, P. J., F. Richard, F. Lorge, Y. Castille, A. Moxhon, R. Opsomer, L. De Visscher, F. X. Wese, and P. Scaillet. Adjuvant radiation therapy does not cause urinary incontinence after radical prostatectomy: results of a prospective randomized study. J Urol, 1998 159:164-6.

497. ASCO 2005 abstract 4513.

498. ASTRO 2005 abstract 0001.

499. Do, L. V., T. M. Do, R. Smith, and R. G. Parker. Postoperative radiotherapy for carcinoma of the prostate: impact on both local control and distant disease-free survival. Am J Clin Oncol, 2002 25:1-8.

500. Garg, M. K., S. Tekyi-Mensah, S. Bolton, J. Velasco, E. Pontes, D. P. Wood, Jr., A. T. Porter, and J. D. Forman. Impact of postprostatectomy prostate-specific antigen nadir on outcomes following salvage radiotherapy. Urology, 1998 51:998-1002.

501. Pisansky, T. M., T. F. Kozelsky, R. P. Myers, D. W. Hillman, M. L. Blute, S. J. Buskirk, J. C. Cheville, R. G. Ferrigni, and S. E. Schild. Radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer. J Urol, 2000 163:845-50.

502. Duchesne GM, Dowling C, Frydenberg M, Joseph D, Gogna NK, Neerhut G, Roberts S, Spry N, Turner S, WooH. Outcome, morbidity, and prognostic factors in post-prostatectomy radiotherapy: an Australian multicenter study. Urology, 2003 61(1): 179-83.

503. Leventis, A. K., S. F. Shariat, M. W. Kattan, E. B. Butler, T. M. Wheeler, and K. M. Slawin. Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy. J Clin Oncol, 2001 19:1030-9.

504. Morris, M. M., K. C. Dallow, A. L. Zietman, J. Park, A. Althausen, N. M. Heney, and W. U. Shipley. Adjuvant and salvage irradiation following radical prostatectomy for prostate cancer. Int J Radiat Oncol Biol Phys, 1997 38:731-6.

505. Anscher, M. S., R. Clough, and R. Dodge. Radiotherapy for a rising prostate-specific antigen after radical prostatectomy: the first 10 years. Int J Radiat Oncol Biol Phys, 2000 48:369-75.

506. Bahnson RR, Hanks GE, Huben RP, Kantoff P, Kozlowski JM, Kuettel M, Lange P H, Logothetis C, Pow-Sang JM, Roach M, 3rd Sandler H, Scardino PT, Taylor RJ, Urban DA, Walsh PC, Wilson TG. “NCCN Practice Guidelines for Prostate Cancer.” Oncology 2000; (Williston Park) 14, 111-9.

507. Kattan MW, Zelefsky M.J, Kupelian PA, Scardino PT, Fuks Z, Leibel SA. “Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer.” J Clin Oncol 2000; 18, 3352-9.

508. Kupelian PA, Kuban D, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A. “Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.” Int J Radiat Oncol Biol Phys 2003; 57, S271-2.

509. Zelefsky MJ, Fuks Z, Hunt M, Lee HJ, Lombardi D, Ling CC, Reuter VE, Venkatraman ES, Leibel SA. “High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer.” J Urol 2001; 166, 876-81.

510. Pilepich MV, Krall JM, al-Sarraf M, John MJ, Doggett RL, Sause WT, Lawton CA, Abrams RA, Rotman M, Rubin P. “Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group.” Urology 45, 1995; 616-23.

511. Hanks GE, Hanlon AL, Epstein B, Horwitz EM. “Dose response in prostate cancer with 8-12 years' follow-up.” Int J Radiat Oncol Biol Phys 2002; 54, 427-35.

512. Lawton CA, Winter K, Murray K, Machtay M, Mesic JB, Hanks GE, Coughlin CT, Pilepich MV. “Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate.” Int J Radiat Oncol Biol Phys 2001; 49, 937-46.

513. Pollack A, Zagars GK, Starkschall G, Antolak JA, Lee JJ, Huang E, von Eschenbach, AC, Kuban DA, Rosen I. “Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial.” Int J Radiat Oncol Biol Phys 2002; 53, 1097-105.

514. Kupelian P, Kuban D, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A. “Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: The combined experience of nine institutions in patients treated in 1994 and 1995.” Int J Radiat Oncol Biol Phys 2005; 61, 415-9.

515. D'Amico AV, Schultz D, Loffredo M, Dugal, R, Hurwitz M, Kaplan I, Beard CJ, Renshaw AA, Kantoff PW. “Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer.” Jama 2000; 284, 1280-3.

516. D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW. “6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.” Jama 2004; 292, 821-7.

517. Denham JW, Steigler A, Lamb DS, Joseph D, Mameghan H, Turner S, Matthews J, Franklin I, Atkinson C, North J, Poulsen M,Christie D, Spry NA, Tai KH, Wynne C, Duchesne G, Kovacev O, D'Este C. “Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial.” Lancet Oncol 2005; 6, 841-50.

518. Roach M, 3rd DeSilvio M, Lawton C, Uhl V, Machtay M, Seider MJ, Rotman M, Jones C, Asbell SO, Valicenti RK, Han S, Thomas CR Jr, Shipley WS. “Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413.” J Clin Oncol 2003; 21, 1904-11.

519. Morris DE, Emami B, Mauch PM, Konski AA, Tao ML, Ng AK, Klein EA, Mohideen N, Hurwitz MD, Fraas BA, Roach M, 3rd Gore EM, Tepper JE. “Evidence-based review of three-dimensional conformal radiotherapy for localized prostate cancer: an ASTRO outcomes initiative.” Int J Radiat Oncol Biol Phys 2005; 62, 3-19.

520. Robinson JW, Moritz S, Fung T. “Meta-analysis of rates of erectile function after treatment of localized prostate carcinoma.” International Journal of Radiation Oncology*Biology*Physics 2002; 54, 1063-1068.

521. Zurlo A, Collette L, van Tienhoven G, Blank L, Warde P, Dubois J, Jeanneret W, Storme G, Bernier J, Kuten A, Pierart M, Bolla M. “Acute toxicity of conventional radiation therapy for high-risk prostate cancer in EORTC trial 22863.” Eur Urol 2002; 42, 125-32.

522. Cooperberg MR, Lubeck DP, Meng MV, Mehta SS, Carroll PR. “The changing face of low-risk prostate cancer: trends in clinical presentation and primary management.” J Clin Oncol 2004; 22, 2141-9.

523. Beyer DC, McKeough T, Thomas T. “Impact of short course hormonal therapy on overall and cancer specific survival after permanent prostate brachytherapy.” Int J Radiat Oncol Biol Phys 2005; 61, 1299-305.

524. Blasko JC, Grimm PD, Sylsvester JE, Cavanagh W. “The role of external beam radiotherapy with I-125/Pd-103 brachytherapy for prostate carcinoma.” Radiother Oncol 2000; 57, 273-8.

525. Potters L, Morgenstern C, Calugaru E, Fearn P, Jassal A, Presser J, Mullen E. “12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer.” J Urol 2005; 173, 1562-6.

526. Sylvester JE, Blasko JC, Grimm PD, Meier R, Malmgren JA. “Ten-year biochemical relapse-free survival after external beam radiation and brachytherapy for localized prostate cancer: the Seattle